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ABSTRACT 
Hypercalcemia of malignancy is the c o m m o n e s t c a u s e of 
hypercalcemia in hospital p o p u l a t i o n and c u r r e n t e v i d e n c e 
suggests that non-metastatic malignant hypercalcemia is mediated 
by a humoral factor known as parathyroid hormone-related 
peptide (PTHRP). 
Primary hepatocellular carcinoma (HCC) which is common in 
Asia was found to be the second commonest cause of malignancy-
associated hypercalcemia in a r e c e n t s u r v e y in Hong K o n g . 
PTHRP produced by tumour acts like parathyroid hormone (PTH) 
in t h e k i d n e y , i n c r e a s e s t h e p r o d u c t i o n a n d e x c r e t i o n of 
nephrogenous cyclic adenosine monophosphate (NcAMP) • 
The purpose of the present study was to investigate the 
mechanism of hypercalcemia in HCC p a t i e n t s by m e a s u r i n g the 
excretion of NcAMP,plasma PTH and PTHRP concentrations. 
In this study, 55 HCC , 8 cirrhotic patients and 14 healthy 
control subjects were recruited. Of the 55 HCC patients, 4 had 
hypercalcemia. 
In a l l s u b j e c t s , s e r u m c a l c i u m , p h o s p h a t e , a l b u m i n , 
creatinine, alkaline phosphatase and PTH were measured. Urinary 
excretion of calcium, phosphate, creatinine, hydroxyproline and 
renal phosphate threshold were also measured • The relative 
contributions of renal tubular reabsorption, bone resorption and 
renal function to the h y p e r c a l c e m i a w e r e c a l c u l a t e d f r o m a 
nomogram for the 4 hypercalcemic HCC patients. 
Using a commercially available radioimmunoassay plasma and 
urine cyclic adenosine monophosphate (cAMP) were measured and 
NCAMP calculated. Serum PTHRP concentration was measured by a 
commercial radioimmimoassay on 2 hypercalcemic HCC patients, 13 
normocalcemic HCC patients ,1 cirrhotic patient and 1 healthy 
control subject. 
The within-run precision of the cAMP assay estimated on 
three commercial urine controls was good with mean coefficient"of 
‘ variation of less than 4 per cent; but the mean coefficient of 
variation for b e t w e e n - r u n p r e c i s i o n was 15 .8 p e r c e n t . F o r 
recovery study, cAMP standard spiked into two commercial urine 
controls had mean recoveries of 89 and 90.5 per cent. 
The incidence of hypercalcemia in HCC patients was about 7 
per c e n t . H y p e r c a l c e m i c HCC p a t i e n t s h a d i n c r e a s e d N c A M P 
excretion.Their serum p h o s p h a t e c o n c e n t r a t i o n s a n d r e n a l 
phosphate threshold were lowered in the presence of suppressed 
serum PTH level.Bone resorption was increased in hypercalcemic 
HCC patients as demonstrated by the increased urinary calcium and 
hydroxyproline excretion. Three hypercalcemic HCC patients had 
bone resorption as the major component of hypercalcemia and one 
- had renal tubular reabsorption as the major component. These 
showed that although they had biochemical features of primary 
hyperparathyroidism but their PTH levels were low . 
Total urinary cAMP expressed as per 100 ml g l o m e r u l a r 
filtrate or as per mmol creatinine had the same discriminatory 
value as N c A M P , 
Serum PTHRP was elevated in the 2 hypercalcemic HCC patients 
in whom it was measured and in 6 out of 13 normocalcemic HCC 
patients • PTHRP was not elevated in the cirrhotic patient and in 
the healthy control subject. It seems likely that PTHRP rise 




In this chapter current knowledge on calcium homeostasis, 
the incidence and etiology of hypercalcemia, the pathogenesis of 
hypercalcemia of primary h y p e r p a r a t h y r o i d i s m and h u m o r a l 
hypercalcemia of malignancy are reviewed . It also attempts to 
review the pathogenesis of hypercalcemia associated with primary 
hepatocellular carcinoma. Lastly, the aim of the present study is 
described. 
1.1 NORMAL CALCIUM HOMEOSTASIS ； 
The amount of calcium in human adult is about 25 mol (1 kg). 
99 per cent of it is in the bone as crystalline hydroxyapatite. 
Extracellular fluid contains approximately 25 mmol (1 g) calcium 
and plasma contains 7.5 mmol (300 mg) • About 125 mmol (5 g) is 
in the exchangeable calcium pool located mainly on the bone-
forming surfaces and in the soft tissues, where it is readily 
accessible. Only about 1 mmol (40 mg) is present in the cytosol 
[1]. 
In plasma, total calcium concentration is 2.2 - 2.6 mmol/l. 
It exists in three states: 45 per cent is non-diffusible protein 
‘ bound (mainly with albumin) ； 10 p e r c e n t is c o m p l e x e d w i t h 
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citrate, lactate, phosphate and b i c a r b o n a t e ; 45 p e r c e n t is 
ionised. Both complexed and i o n i z e d forms are d i f f u s i b l e . 
Ionised calcium is the physiologically active form which is in 
equilibrium with the other forms. The plasma concentration of 
ionised calcium is 1.15 to 1.3 mmol/1. Protein concentration and 
pH affect the equilibrium. Acidosis favours the dissociation of 
the protein bound calcium and raises the ionised fraction while 
alkalosis has the opposite effect. Formulas are also used to 
calculate the corrected calcium level by taking into account the 
serum total protein or albumin level. 
Calcium is absorbed in the d u o d e n u m by a c t i v e p r o c e s s 
involving calcium binding protein synthesised under the influence 
of 1,25-dihydroxycholecalciferol (1,25-(OH)2D3)• About 5 mmol is 
absorbed daily from dietary intake of about 25 mmol. Absorption 
is increased by acid medium in the d u o d e n u m , i n d i r e c t l y by 
parathyroid hormone (PTH), high p r o t e i n d i e t , p r e g n a n c y and 
calcium deprivation; and is d e c r e a s e d by a l k a l i n e m e d i u m in 
duodenum, presence of fat, oxalates, phosphates and phytates. 
Urinary excretion of calcium roughly equals the net intestinal 
calcium absorption. Approximately the same amount is exchanged 
between the bone surface and the extracellular fluid each day 
during bone remodelling. Faecal calcium represents unabsorbed 
dietary calcium.Each day, about 0.25 mol calcium is filtered 
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through the glomerulus and 98 per cent is reabsorbed by the renal 
tubules. About 65 per cent is reabsorbed by the proximal tubule 
passively linked with sodium and water reabsorption, 20 — 25 per 
cent is reabsorbed in the a s c e n d i n g loop of H e n l e and the 
remaining 10 per cent in the distal tubule by active process 
influenced by PTH and 1,25-(OH)2D3. 
Extracellular fluid calcium is regulated by three systemic 
hormones: PTH, l,25-(OH)2D3 (calcitrol) and calcitonin. Each 
hormone is controlled either directly or indirectly by plasma 
ionised calcium through either positive or negative feedback 
mechanisms. The maintenance of plasma calcium within a narrow 
range depends on the transport of calcium across three organs: 
the gut, the kidney and the bone. PTH and calcitrol are clearly 
more important than calcitonin, as persistent alternations in 
calcium homeostasis do not occur in the absence of the thyroid 
gland or with tumours of calcitonin secreting cells (in medullary 
thyroid carcinoma) [2]. Calcitonin is produced by the C-cells of 
the thyroid gland, its major physiological role is probably to 
inhibit resorption of bone by i n h i b i t i n g the a c t i v i t y of 
osteoclasts when PTH and calcitrol levels are high [3]• 
PTH is synthesised in the chief cells of the parathyroid 
gland in the form of a 115 amino acid single chain precursor 
called "preproPTH". Very little "preproPTH" exists in plasma 
• because of rapid cleavage of the N-terminal leader sequence while 
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the amino acids are still assembled distally .PTH is an 84 amino 
acid molecule • This molecule is d e g r a d e d b o t h w i t h i n the 
parathyroid gland and at peripheral sites to form biologically 
active N-terminal fragments and biologically inactive mid-region 
fragments and the C-terminal fragments. The first 34 amino acids 
of the N-terminal are essential for the biological activity 
[4,5] . The intact molecule and the N-terminal fragments have much 
shorter half-lives because they are degraded in the liver and at 
other sites. C-terminal fragments are cleared only by glomerular 
filtration, and their concentration in the peripheral blood is 
dependent on renal function. In normal individuals, the half-life 
of the intact molecule is about 5 minutes and that of the C-
terminal fragment is about 30 minutes. In patients with renal 
failure, the half-life of the C-terminal fragments increases to 
between 24 and 36 h o u r s . C i r c u l a t i n g N - t e r m i n a l f r a g m e n t s 
generally represent a minor component of biologically active PTH, 
t h e m a j o r c o m p o n e n t b e i n g t h e i n t a c t m o l e c u l e [ 6 ] . 
The actions of PTH are: stimulation of phosphate excretion, 
reabsorption of calcium at the distal tubules and bone resorption 
；since PTH mobilizes calcium from bone, the amount of calcium 
excreted is eventually increased but the proportion of filtered 
load that is reabsorbed is also raised. PTH also stimulates 1 -
hydroxylation of 25-hydroxycholecalciferol (25-(OH)D3) in the 
kidney to the active l,25-(OH)2D3 which increases calcium and 
phosphate absorption in the gut. The action of PTH on the kidney 
occurs within seconds to minutes, whereas its effects on the bone 
and gut require h o u r s to days [6]. 
Cholecalciferol (D3) is s y n t h e s i s e d in the skin from 7— 
dehydrocholesterol in response to sunlight. D3 is not an active 
horiDone u n t i l it u n d e r g o e s h y d r o x y 1 at i o n s • T h e f i r s t 
hydroxylation occurs in the liver to 25-（0H)D3. The s e c o n d 
hydroxylation occurs in the kidney to the active 1 , 2 5 - ( O H ) . 
Z J 
Synthesis of l,25-(OH)2D3 is. stimulated by PTH and low serum 
phosphate level.The major physiological role of l,25-(OH),D) is 
^ J 
to promote intestinal absorption of calcium and phosphate for 
. mineralization of b o n e . It is the m o s t p o t e n t of all b o n e 
resorbing hormones on molar basis. When there is insufficient 
intake of calcium and phosphate for mineralization, the supply of 
these ions can only be obtained by l,25-(OH)2D3 stimulated bone 
r e s o r p t i o n w h i c h s t i m u l a t e s the n u m b e r a n d a c t i v i t y of 
osteoclasts. 
When plasma ionised calcium decreases, PTH production and 
release are stimulated. Through its actions on the gut, kidney 
and bone, PTH normalises the calcium level. Under physiological 
conditions, the actions of PTH on the gut and kidney are more 
important than its action on bone resorption. When plasma ionised 
calcium increases, PTH production and release are inhibited , 
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thus lowering the calcium level. Therefore calcium homeostasis is 
finely tuned to maintain plasma c a l c i u m l e v e l w i t h i n n a r r o w 
limits. Also renal capacity to excrete calcium is large and can 
be increased to about five fold to maintain extracellular fluid 
calcium level [2]. 
Apart from the three main calcium-regulating hormones, there 
are other humoral and local f a c t o r s that are u n d o u b t e d l y 
important. Among these are; c a t e c h o l a m i n e s , v a r i o u s g r o w t h 
factors (epidermal transforming , fibroblast and platelet derived 
growth factors), thyroxine, C o r t i s o l , sex h o r m o n e s , g r o w t h 
hormones and insulin {acting through somatomedians),local factors 
(prostaglandin E2, monokines, o s t e o c l a s t a c t i v a t i n g f a c t o r , 
i n t e r l e u k i n - 1 ) a n d i m m o b i l i z a t i o n [ 3 ] . M o r e r e c e n t l y , a 
parathyroid hormone-related peptide has been characterized in 
patients with humoral hypercalcemia of malignancy • this peptide 
is also called "humoral hypercalcemia of malignancy factor" (HHM-
factor) [6]. 
1.2 THE INCIDENCE AND COMMON C A U S E S OF H Y P E R C A L C E M I A IN 
HOSPITAL POPULATION 
The incidence of hypercalcemia depends on the population 
studied, the reference interval and the r e l i a b i l i t y of the 
method. In most laboratories, the upper limit of the reference 
range is 2.6 mmol/l. 
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A recent study in Hong Kong showed that the incidence of 
hypercalcemia in hospital population is about 0.6 per cent [7]. 
T h e m a i n c a u s e s of h y p e r c a l c e m i a in t h a t s t u d y w e r e 
m a l i g n a n c y ( 7 2 . 1 %) t u b e r c u l o s i s (6.0 %) a n d p r i m a r y 
h y p e r p a r a t h y r o i d i s m (5.5 %) . In m a l i g n a n c y - a s s o c i a t e d 
hypercalcemia, carcinoma of the lung was the co醒onest cause 
(31.8 %) followed by hepatocellular carcinoma (10.2 %), carcinoma 
of oesophagus (10.2 %) , haematological malignancy (7.6 %) and 
nasopharyngeal carcinoma (6.8 %) and carcinoma of the breast was 
not common (3.0 %) • In another study in South Africa, the same 
incidence of 0.6 per cent of hypercalcemia in hospital population 
was observed [8]. They showed that hypercalcemia was transient 
in 19.2 per cent of patients and sustained in the remainder. The 
commonest causes in the sustained group were malignancy (45 % ) , 
thiazide diuretic therapy (21 %) and primary hyperparathyroidism 
(16.5 %).The major malignancies associated with hypercalcemia 
were the lung (30 %) , followed by urogenital (15 %), gastro-
intestinal (13 %) and breast (8 % ) . 
These studies show that the p a t t e r n of m a l i g n a n c y -
a s s o c i a t e d h y p e r c a l c e m i a r e f l e c t s t h e l o c a l p a t t e r n of 
malignancy. In another study in a cancer institute in which 22.4 
p e r c e n t of a d m i t t e d p a t i e n t s h a d n e o p l a s m s . Of a l l t h e 
admissions ,the overall incidence of hypercalcemia was 5 per 
7 
cent; of these patients, 38 per cent had malignancy and 19.6 per 
cent had primary h y p e r p a r a t h y r o i d i s m (PHP) [ 9 ] . T h e h i g h 
incidence of hypercalcemia in that study is not comparable to 
that of a general hospital because of the selective nature of the 
patients studied-
malignancy is the major cause of hypercalcemia in hospital 
patients , whereas PHP is the major cause in ambulatory patients 
[4] • The prevalence of hyperparathyroidism in Hong Kong is 1 in 
3,000 which is lower than other reports [7-9]. 
Interestingly, tuberculosis was one of the major causes of 
hypercalcemia in Hong K o n g , p r o b a b l y r e f l e c t i n g the h i g h 
incidence of t u b e r c u l o s i s in the t e r r i t o r y . T h e m e c h a n i s m of 
hypercalcemia in t u b e r c u l o s i s is t h o u g h t to be due to the 
increased production of l,25(OH)2D3 by macrophages [6,7]. 
Other common causes of h y p e r c a l c e m i a i n c l u d e v i t a m i n D 
intoxication, sarcoidosis, thyrotoxicosis , thiazide diuretics, 
Paget's d i s e a s e , fractures with i m m o b i l i z a t i o n , m i U - a U a l i 
syndrome, familial hypocalciuric hypercalcemia, Addison's disease 
and acromegaly [6]. 
Intoxication by vitamin D is caused by acute or chronic 
administration of large doses of the vitamin. Vitamin D and its 
metabolites are lipid soluble and are stored mainly in adipose 
t i s s u e , and therefore have very h a l f - l i v e s . L o n g p e r i o d s a r e 
required for the plasma vitamin D levels to return to normal. 
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Hypercalcemia associated with sarcoidosis is characterized 
by increased intestinal absorption of calcium, hypercalciuria and 
increased serum l,25-(OH)2D3 l e v e l s . It has b e e n shown that 
macrophages in sarcoidosis has 1 一 a l p h a — h y d r o x y l a s e w h i c h 
converts 25-(OH)D3 to l,25-(OH)2D3 [6] . PTH s e c r e t i o n is 
suppressed in sarcoidosis as a response to hypercalcemia. 
Small increases in serum calcium concentration is found in 
hyperthyroidism. The cause of hypercalcemia is unknown,but may be 
d u e to t h y r o x i n e m e d i a t e d b o n e r e s o r p t i o n a n d i n c r e a s e d 
intestinal absorption of calcium [6]. Therefore, hyperthyroidism 
must be controlled before parathyroid function can be evaluated 
in these patients. 
Thiazide diuretics cause h y p e r c a l c e m i a p a r t i c u l a r l y in 
p a t i e n t s w i t h u n d e r l y i n g b o n e d i s e a s e . T h e e t i o l o g y is 
multifactorial with contributions from haemoconcentration,reduced 
urinary calcium excretion and enhanced bone resorption [6]. 
P a g e t , s d i s e a s e r a r e l y c a u s e s h y p e r c a l c e m i a e x c e p t 
during periods of immobilization when bone resorption is greater 
than bone formation. 
H y p e r c a l c e m i a in m i l k - a l k a l i s y n d r o m e is d u e to t h e 
prolonged intake of milk and absorbable alkali antacids (usually 
calcium carbonate) . This is b e c o m i n g less c o m m o n b e c a u s e of 
reduced use of absorbable antacids. The alkalosis induced by the 
alkali ingestion also lowers urine calcium excretion. Serum PTH 
level generally is suppressed in milk-alkali syndrome. 
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Familial hypocalciuric hypercalcemia is autosomal dominantly 
inherited and most affected subjects are asymptomatic [6].The key 
feature of this disorder is the low urinary calcium excretion 
relative to the serum calcium concentration, as a consequence of 
increased tubular r e a b s o r p t i o n of c a l c i u m . 
In Addison's disease, significant hypercalcemia is rare. The 
cause of hypercalcemia is unknown though it is suggested that 
intestinal calcium absorption may be enhanced in the absence of 
glucocorticoids [6]. 
In a c r o m e g a l y , 15 - 20 p e r c e n t of p a t i e n t s a r e 
hypercalcemic. The cause is unknown but may be due to increased 
production of l,25-(OH)2D3 [6]. 
1.3 HYPERCALCEMIA IN PRIMARY HYPERPARATHYROIDISM 
Primary hyperparathyroidism (PHP) is the commonest cause of 
hypercalcemia in ambulatory persons [6]. A single adenoma is 
responsible for PHP in most patients (80 - 85 %) ；in up to 10 
per cent of patients, the adenoma is found in ectopic, sites such 
as the lateral neck. It is unusual for a patient to harbour two 
adenomas concurrently. The other form of PHP is the chief cell 
hyperplasia affecting all four glands. PHP has a female sex 
ponderance (about 3 : 1) and is more frequent in older 
10 
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persons. Conventional description of patients presenting with “ 
Stones, Bones and Groans" may not be readily appreciated nowadays 
because of the availability of early diagnosis. The corner stone 
for the diagnosis of PHP is the measurement of serum calcium 
concentration. At least three determinations should be performed 
to establish persistent hypercalcemia [6]. 
The signs and symptoms of PHP are related to hypercalcemia, 
such as polyuria, polydipsia, gastrointestinal tract dysfunction 
(anorexia, constipation) and e l e c t r o c a r d i o g r a p h i c s i g n s ( 
shortened QT interval) [10]• These signs and symptoms are not 
specific to PHP but rather are c o m m o n to all h y p e r c a l c e m i c 
disorders. Bone and stone disease are classic manifestations of 
PHP. However osteitis fibrosa cystica, the chronic severe form of 
skeletal manifestation is rarely seen today.Hyperparathyroid bone 
d i s e a s e a l s o l e a d s to g e n e r a l d e m i n e r a l i z a t i o n a n d 
o s t e o p o r o s i s . T h e k i d n e y is t h e o t h e r m a j o r a f f e c t e d 
o r g a n . Nephrol it hi as is or n e p h r o c a l c i n o s i s is p r e s e n t in 
approximately 10 per cent of PHP [10]. In some patients, decrease 
in glomerular filtration rate is the sole renal manifestation of 
PHP. Peptic ulcer disease and acute pancreatitis are believed to 
be associated with hyperparathyroid state [10].However it remains 
to be established that these l i n k a g e s are f i r m l y b a s e d on 
pathophysiological grounds. 
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Serum calcium level is elevated in PHP due to the actions of 
excess PTH on the gut, the kidney and bone as described earlier. 
Bone turnover is stimulated with an increase in bone formation 
(osteoblastic activity) and resorption (osteoclastic activity) 
[2]. Accompaning the hypercalcemia which is usually in the range 
of 2.55 to 3.0 mmol/1 in PHP, the serum phosphate concentration 
and renal phosphate threshold are d e c r e a s e d . Serum a l k a l i n e 
phosphatase level may be elevated if there is a substantial bone 
osteoblastic acitvity. The urinary excretion of hydroxyproline, a 
marker of bone turnover, will also be elevated. PTH influences 
acid-base handling in the k i d n e y and can lead to a m i l d 
hyperchloremic acidosis in some patients. 
NcAMP excretion is increased in PHP due to the actions of 
PTH on the kidney.In concert with elevated serum PTH, 1,25-
(OH)2D3 level in plasma is elevated in a substantial number of 
patients in PHP . Calcium e x c r e t i o n is o f t e n m o d e r a t e l y 
increased (about 7.5 to 12.5 mmol/ day ) inspite of increased 
tubular reabsorption. This is b e c a u s e of the l a r g e load of 
calcium filtered by the glomerulus [6] . Some p a t i e n t s w i t h 
malignancy may have an elevated level of serum PTH because of 
coexistence of PHP and malignancy [11]. 
Parathyroid carcinoma, a rare form of PHP accounts for less 
than one per cent of patients. The ratio of affected women to men 
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is higher than in benign parathyroid disease and patients with 
parathyroid carcinoma tend to be younger by one decade than the 
average patient with benign adenoma. Both serum PTH and calcium 
concentration are higher in parathyroid carcinoma than PHP . 
Parathyroid carcinoma patients frequently have both renal and 
skeletal involvements which is rare in benign PHP [10]. 
1.4 HYPERCALCEMIA OF MALIGNANCY 
Cancer-associated hypercalcemia has been recognized since 
early 1920‘s . The overall i n c i d e n c e of h y p e r c a l c e m i a in 
malignancy is about 8.5 per cent [3] • The pathophysiology of 
cancer-associated hypercalcemia has been reviewed extensively [12-20]. 
Mundy and Martin divided hypercalcemia of malignancy into 
three types based on the nature of the underlying disease [13]. 
The first type of cancer-associated hypercalcemia (50-70 %) is 
hypercalcemia in solid tumours with bony metastases. The two 
commonest causes are lung and breast cancer. Approximately 25 per 
cent of unselected hypercalcemic patients with malignancy have 
breast cancer, making it the second common cause of hypercalcemic 
malignancy after lung cancer. It was believed that hypercalcemia 
is caused by direct erosion of the bone by tumour c e l l s , 
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osteoclasts, lymphocytes and local secretion of prostaglandins. 
This is clearly an over simplification,as an inverse rather 
than direct correlation was found between the number of bony 
metastases and the serum calcium l e v e l in p a t i e n t s w i t h 
hypercalcemia of malignancy [21]. Also, bone scan study has found 
no positive correlation between the extent of metastatic disease 
and serum calcium level [22]. The e x a c t m e c h a n i s m of b o n e 
destruction by tumour cells is unknown, but tumour extracts have 
been found to have the capacity to resorb bone in vitro[23,24]. 
Increased renal reabsorption of calcium was observed in breast 
cancer, possibly mediated by a humoral factor (or factors) with 
activity similar to PTH [25] • The majority of breast cancers do 
not produce PTHRP, but there are n u m e r o u s o t h e r o s t e o t r o p i c 
factors produced by the breast cancer c e l l s that c o u l d be 
important, including transforming growth factors (alpha and beta) 
and platelet derived growth f a c t o r ; any one of these can 
stimulate bone resorption [19]. Prostaglandins are unlikely to be 
responsible for hypercalcemia in malignancy unless the tumour is 
very large as in renal cortical carcinoma [13]. 
The second type of cancer—associated hypercalcemia (10-20 %) 
is hypercalcemia in solid tumours without bony metastases.This 
type is also called humoral hypercalcemia of malignancy (HHM)• 
These are generally associated with squamous cell carcinomas of 
- the lung, kidney, ovary, head or neck, pancreas, liver, large 
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bowel, oesophagus and skin. Hypercalcemia in these patients is 
believed to be the result of a recently discovered humoral factor 
called humoral hypercalcemia factor (HHM-factor) or parathyroid 
hormone-related peptide (PTHRP) [13,15,17]. Recently, it was 
found that in patients with breast cancer, the development of 
hypercalcemia is related to the presence of liver metastases 
[26]. Hypercalcemia in these patients could arise either from 
increased production or decreased clearance of a humoral factor. 
A high incidence of increased NcAMP excretion in normocalcemic 
patients with bironcliogenic carcinoma has been observed [17] . This 
suggests that the increased production of PTHRP occurs quite 
commonly in these cancers.Factors other than PTHRP have been 
proposed as potential mediators of bone resorption and these 
i n c l u d e t r a n s f o r m i n g g r o w t h f a c t o r s ( a l p h a a n d b e t a ) , 
prostaglandins, leukocytes, cytokines, 1,25-(OH)2D3 and colony 
stimulating factors. The exact r o l e of t h e s e s u b s t a n c e s in 
causing bone resoption is unknown at present, but it is likely 
that there is a complex interaction of multiple factors including 
PTHRP on bone resorption [19,27]. 
Haematological malignancies (20-40 %) are the third type of 
cancer-associated hypercalcemia. They include multiple myeloma, 
lymphosarcoma, Hodgkin's disease, leukemia, Burkitt‘s lymphoma 
and T-cell lymphoma. Contributing factors to the hypercalcemia in 
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this group of malignancies include osteoclast activating factor 
(comprising of at least tumour necrosis factors alpha and beta), 
interleukins, lymphokins and prostaglandins [13]. The etiological 
role of PTHRP in the hypercalcemia of haematological malignancies 
is unknown. These patients exhibit a generalized increase in bone 
resorption as shown by histology and bone scan, yet they do not 
have increased excretion of NcAMP. Recently,it was reported that 
hypercalcemia in T-cell lymphomas and Hodgkin's disease appeared 
to be mediated by tumour produced l,25-(OH)2D3 in concert with 
other factors [28,29]. 
The classification described by Mundy and Martin is helpful 
from a clinical standpoint, but it must be n o t e d that t h e s e 
mechanisms of hypercalcemia are not n e c e s s a r i l y m u t u a l l y 
exclusive. 
1.5 PATHOPHYSIOLOGY OF HUMORAL HYPERCALCEMIA OF MALIGNAHCY 
Although humoral hypercalcemia of malignancy (HHM) is not 
the most common form of h y p e r c a l c e m i a , it has been the m o s t 
studied form mainly because of the possibility of identifying a 
precise pathogenic factor. 
In HHM, hypercalcemia is usually rapidly progressive and is 
associated with low plasma phosphate and a mild hypokalaemic 
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alkalosis [13] • The major clinical entity to differentiate it 
from is PHP. In general HHM patients are more symptomatic-i.e. 
nausea, vomiting, anorexia, p o l y u r i a , p o l y d i p s i a , t h i r s t , 
constipation, lethragy, confusion, stupor and eventually coma. 
R e n a l e f f e c t s of h y p e r c a l c e m i a a r e d e c r e a s e d g l o m e r u l a r 
filtration rate (GFR),decreased renal plasma flow,natriuresis and 
volume depletion [30].These effects greatly increase the risk of 
acute azotemia and further hypercalcemia. 
Biochemical features of HHM in common with PHP are: elevated 
plasma calcium level, low plasma p h o s p h a t e l e v e l , i n c r e a s e d 
NcAMP, normal or mild increase in plasma alkaline phosphatase 
(ALP) level. The HHM patients usually have higher ALP levels than 
PHP patients. Both PHP and HHM patients have increased urinary 
calcium excretion in spite of increased tubular reabsorption , 
because of the large filtered load by the glomerulus. Both groups 
of patients have reduced renal phosphate threshold expressed as 
maximum excretion of phosphate per litre of glomerular filtrate 
(TMP/GFR). 
Despite these similarities with PHP, there are features that 
are different between HHM and PHP [2,6,13,30,31]• HHM patients 
have higher increase in serum calcium concentration in the range 
of 2.8 to 3.8 mmol/l. Plasma albumin and chloride levels are 




malignancy, serum calcium c o n c e n t r a t i o n m a y o c c a s i o n a l l y be 
normal but the ionised fraction is elevated. Metabolic alkalosis 
is common in HHM whereas metabolic acidosis is more common in 
PHP [31].But as serum chloride , bicarbonate and ALP levels vary 
widely, they are of little help in the differential diagnosis of 
HHM and PHP. In PHP, l,25-(OH)2D3 level in plasma is elevated in 
a substantial number of p a t i e n t s , but is d e c r e a s e d in HHM 
patients; this may be due to the s u p p r e s s i o n of 1 - a l p h a -
hydroxylase by PTHRP [32] • Plasma PTH level is high in PHP but 
is suppressed in HHM. Calcium absorption in the gut is increased 
in PHP but is decreased in HHM. Urinary hydroxyproline , a 
marker of bone turnover, is i n c r e a s e d in b o t h PHP and HHM 
patients; but HHM patients have h i g h e r u r i n a r y e x c r e t i o n . 
Osteocalcin, a vitamin—K—dependent protein synthesised by the 
osteoblast is increased in PHP but is n o r m a l or low in HHM 
patients [33]. This suggested that HHM patients have uncoupled 
b o n e r e s o r p t i o n—i • e • i n c r e a s e d b o n e r e s o r p t i o n w i t h o u t 
accompaning bone formation. In PHP patients, there is increased 
bone turnover, with increases in both b o n e f o r m a t i o n and 
r e s o r p t i o n . T h e b i o c h e m i a l f e a t u r e s of P H P T and H H M a r e 
summarized in Table 1. 
The syndrome of HHM is quite d i s t i n c t from P H P ; for 
example:osteoclastic bone resorption is much more prominent in 
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Table 1. Biochemical features of primary hyperthyroidism 
and humoral hypercalcemia of malignancy 
Primary Humoral hypercalcemia 
hyperparathyroidism of malignancy 
Serum calcium 个 令个 
Serum phosphate + j 
Renal phosphate threshold 4 | 
Serum PTH 个个 N or | 
NcAMP 令 个 
1,25-dihYdroxycholecalciferol 个 + 
Urinary calcium excretion 个 令令 
Urinary hydroxyproline excretion t | ^ 
NcAMP: Nephrogenous cyclic adenosine monophosphate ； PTH: parathyroid hormone 
小：increase, 令：decrease, N: normal 
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HHM than in PHP. PTHRP cannot explain all the known biochemical 
features of HHH. There is a possibility that the effects of PTHRP 
on the target organs are modified by other factors [19] such as ： 
epidermal growth factor and transforming growth factor-alpha 
[34,35], interleukin-l-alpha [36,37] and tumour necrosis factors 
(alpha and beta) [38]. 
Although hypercalcemia is a common complication of cancer , 
early recognition and prevention of hypercalcemia can greatly 
reduce morbidity [39,40]. 
1.6 PATHOGENESIS OF HUMORAL HYPERCALCEMIA OF MALIGNANCY-
EVIDENCE FOR A PARATHYROID HORMONE-RELATED PEPTIDE 
Some of the features of HHM mimic PHP, but it is now clear 
that native PTH is not responsible for this syndrome. It was 
shown that extracts of several tumours from patients with HHM 
were capable of causing bone resorption in vitro,but PTH could 
not be detected despite the use of different antisera with broad 
s p e c i f i c i t i e s [23 , 24] • P r e v i o u s l y , t h e p r e s e n c e of b o n e 
metastases was generally accepted as sufficient explanation of 
hypercalcemia. However, certain tumours that commonly invade bone 
( e x a m p l e : oat cell and prostate c a r c i n o m a ) , r a r e l y c a u s e 
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hypercalcemia [24]. Also, no correlation was observed between the 
extent of metastases and serum calcium level [21,22]. Increased 
osteoclastic activity particularly on the trabecular surfaces and 
decreased bone formation was found in HHM syndrome [41]• 
The humoral basis of HHM p r o p o s e d by A l b r i g h t [12] w a s 
supported by two studies that d e s c r i b e d p a t i e n t s who had 
hypercalcemia 
in the absence of skeletal tumour involvement and 
朴 o s e hypercalcemia was c o r r e c t e d by e l i m i n a t i n g the t u m o u r 
[ 4 2 , 4 3 ] . A l s o , c u l t u r e d r e n a l c a r c i n o m a c e l l s f r o m a 
hypercalcemic patient; when grown in nude mouse, produced marked 
hypercalcemia that was reversed by r e s e c t i o n of the t u m o u r . 
Furthermore,this cell line produced a protein that was shown to 
be recognized by PTH receptors [44]• 
PTH is not a contributing factor in HHM because serum PTH 
level is suppressed. Furthermore, turaours from HHM patients when 
examined for the presence of PTH messenger RNA (mRNA), revealed 
negative results [45] . Conversely, human PTHRP mRNA was detected 
in cancer tissues from HHM patients, but was not detected in 
normocalcemic cancer patients [46]. In another more recent study, 
PTHRP mRNA was found in tumours complicated by hypercalcemia as 
v/ell as in normocalcemic p a t i e n t s w h o s e t u m o u r types are 
frequently complicated by hypercalcemia, but was not found in 
tumours that are rarely complicated by hypercalcemia [47]• 
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The major area of controversy in this field is the relative 
importance of bone resorption c o m p a r e d w i t h i n c r e a s e d r e n a l 
calcium reabsorption in the pathogenesis of HHM. It has been 
shown that increased resorption alone is insufficient to cause 
hypercalcemia in HHM [22], and renal effects may contribute quite 
substantially to hypercalcemia in HHM [22,32,48,49]• One group 
has attempted to determine the relative contributions of each 
u n d e r l y i n g f a c t o r to H H M . T h e i r r e s u l t s s h o w e d t h a t in 
hypercalcemic breast cancer, about 46 percent of the increment in 
extracellular calcium was attributable to bone resorption, 40 per 
cent was attributable to increased renal calcium reabsorption and 
the remainder being accounted by reduced glomerular function 
[25]. 
The most direct evidence of the contributory role of PTHRP 
in HHM is the isolation of PTHRP from tumours. In 1987, three 
groups simutaneously reported the isolation and sequenced the N-
terminus of PTHRP from three tumours associated with HHM. The 
molecular weight was found to be b e t w e e n 1 6 , 0 0 0 and 1 7 , 0 0 0 
daltons [50-52]. Shortly thereafter, a nearly identical protein 
was identified in extracts of tumours causing a similar syndrome 
in animals [53]. PTHRP was shown to be a protein produced by 
tumours associated with HHM that acts through the PTH receptor; 
but is immunologically [18, 50, 54 , 55] and b i o c h e m i c a l l y [56] 
distinct from PTH. 
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Based upon the isolated PTHRP, complementary DNA (cDNA) has 
been used to encode a "prepro-peptide" of 36 amino acids and a 
mature protein of 141 amino acids that has 67 per cent homology 
with PTH in the N-terminal region [57,58]. Eight of the first 13 
N-terminal residues are identical to human PTH (hPTH).However 
antisera directed to the N-terminus of PTHRP does not recognize 
PTH. The striking homology with PTH in the N-terminal region is 
however not maintained in the remainder of the molecule [57]. 
On the basis of cDNA clones, s y n t h e t i c PTHRP h a v e b e e n 
synthesised to study the in vivo and in vitro effects of PTHRP. 
More recently, recombinant PTHRP(1-141) has been expressed in E 
coli [32]. Studies with synthetic PTHRP showed that PTHRP mimics 
the effects of PTH, namely activation of adenylate cyclase in 
bone and kidney ,resulting in i n c r e a s e d N c A M P and p h o s p h a t e 
excretion, increased renal calciup reabsorption and enhanced bone 
resorption [59,60] . NcAMP is regarded as a sensitive and specific 
index of PTH or PTHRP bioactivity [61-66]. 
Perfused rat kidney was used to c o m p a r e the a c t i o n s of 
hPTH(l-34} with PTHRP(1-34), and it was shown that PTHRP(1-34) 
was more potent than hPTH(l-34) in increasing cAMP and phosphate 
excretion and enhancing calcium reabsorption in the kidney [67]. 
PTHRP obtained from a human lung cancer cell line (BEN) had a 
specific biological activity about six times greater than bovine 
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PTH(1-34) in stimulating cAMP production in osteoblast-like cells 
[51] .In Yi：^ and in vitro studies in thyroparathyroidectomized 
rat have indicated that PTHRP(l-34) was six to ten times more 
potent than hPTH(l-34) in r a i s i n g s e r u m c a l c i u m l e v e l s , in 
suppressing calcium excretion and stimulating NcAMP excretion 
[68,69].PTHRP also stimulated l,25-(OH)2D3 formation in vitro, 
but as 1,25-(0H)2D3 elevation is not usually found in HHM,which 
may be due to suppressed production by elevated serum calcium in 
HHM [59]. 
Synthetic PTHRP was found to be a potent agonist of renal 
membrane and bone cell adenylate cyclase and stimulated calcium 
release from fetal rat long bones [68]. Also, synthetic adenylate 
cyclase stimulating proteins obtained from HHM tumours decreased 
the rate of sodium dependent p h o s p h a t e t r a n s p o r t in r e n a l 
e p i t h e l i a l cells and its i n h i b i t o r y a c t i v i t y w a s r o u g h l y 
equipotent to that of hPTH(l-34) [49,70]. 
PTHRP caused a fall in urinary pH which is reflected in the 
hypokalaemic alkalosis of HHM patients. Urinary pH was found to 
be decreased after PTHRP(1-34) treatment and remained relatively 
constant after hPTH(l-34) in perfused rat kidney . This points to 
differences in their actions on the nephrons [67] • The actions of 
PTHRP can be blocked by antisera to PTHRP and also PTHRP antibody 
lowered serum calcium in mouse with HHM tumours.The antisera to 
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PTH with various regional specificities were however, incapable 
of inhibiting the activity of PTHRP on serum calcium and urinary 
CAMP production [54,55]. 
R e c e n t l y , hybridizing t r a n s c r i p t s e n c o d i n g P T H R P w e r e 
identified in mRNA from a variety of human and animal tumours 
with HHM [71] • In another study, it was shown that HHM patients 
with squamous cell carcinoma of the bronchus , hepatocellular 
cazrcinonia, breast cancer and oesophageal carcinoma had increased 
serum PTHRP levels that c o r r e l a t e d w e l l w i t h s e r u m c a l c i u m 
concentration [72].The current state of knowledge regarding the 
role PTHRP in HHM indicates that this protein is likely to be 
central in the pathogenesis of this syndrome. 
A physiological role for PTHRP has been suggested in view 
of the presence of PTHRP gene which has been mapped to the 
short arm of chromosome 12 in humans and chromosome 2 in the rat 
[32,73]• Chromosome 12 is thought to have arisen by duplication 
of chromosome 11, which carries the PTH gene. PTHRP , therefore, 
represents a previously u n r e c o g n i z e d h o r m o n e w h i c h m a y h a v e 
arisen from the PTH gene by gene duplication. 
Using immunohistochemical peroxidase staining method with 
antiserum raised against P T H R P , P T H R P w a s f o u n d in s p i n o u s 
keratinocytes of normal skin [73]. Its physiological role in skin 
is largely unknown. Recent evidence suggests that it may have 
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both an autocrine and paracrine role in increasing intracellular 
calcium in keratinocytes and stimulates the differentiation of 
these cells [32]. Synthetic PTHRP was shown to stimulate the 
biosynthesis of fibronectin by human dermal fibroblast and also 
appears to possess transforming growth-factor like properties, 
yet PTH does not display either of these properties [74] . These 
qualitative differences between PTH and PTHRP may be relevant to 
their differences in physiological role. 
A physiological role of PTHRP in foetal calcium metabolism 
and in lactation has been s u g g e s t e d . The m a m m a l i a n f o e t u s 
maintains a higher plasma calcium level than the.maternal plasma 
by a placental calcium pump, but PTH level is low in the foetus 
than in the mother. However, PTH like activity , measured by the 
sensitive cytochemical assay is higher in the foetus than in the 
mother [75]. Therefore,it has been suggested that PTHRP may be 
the factor responsible for maintaining the placental calcium 
gradient. PTHRP mRNA of 1.5 kilo-base was found to be expressed 
in lactating mammary glands and extracts from lactating mammary 
tissue could stimulate PTH dependent adenylate cyclase [76]. 
PTHRP may be responsible for mobilizing calcium from mammary 
tissue to the milk during lactation. Interestingly, large amounts 
of PTHRP was detected in milk, which is at least 1,000 times 
higher than the serum level [77]. 
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Another recent study showed that PTHRP mRNA was also present 
at low levels in normal parathyroid tissue and was over expressed 
in parathyroid adenomas [78]. 
Obviously, the full physiological spectrum of PTHRP has yet 
to be defined, it may be playing many more physiological roles 
than currently know. Also, the application of sensitive assays 
for PTHRP in plasma would be e x p e c t e d to h e l p in the e a r l y 
diagnosis of squamous cell carcinoma, in monitoring treatment and 
the detection of recurrence [17] • 
1.7 HYPERCALCEMIA IN PRIMARY HEPATOCELLULAR CARCINOMA 
In Hong Kong, HCC is the second commonest cause of cancer-
associated hypercalcemia [7] • The incidence of HCC in Hong Kong 
is 32 per 100,000 of the male population; which is 30 times that 
of the West. The ratio between male and female is 10:1 [79]. 
Studies in Hong Kong showed that HCC is strongly associated with 
h e p a t i t i s B v i r u s (HBV) i n f e c t i o n a n d c i r r h o s i s [ 8 0 ] . 
The etiology of HCC has been reviewed extensively [81-86]. 
The incidence of hypercalcemia in HCC is 5.3 per cent and in 
cholangiocarcinoma is 17.5 per cent [87] . However, the incidence 
is 69 per cent in sclerosing hepatocellular carcinoma which is 
characterized by intense fibrosis [88].It has been shown that 
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hypercalcemia in HCC is not due to h y p e r p a r a t h y r o i d i s m or 
hypervitaminosis D [89]. PTHRP is strongly suggested to play a 
role in the development of h y p e r c a l c e m i a in HCC p a t i e n t s . 
Arteriovenous and venovenous g r a d i e n t s of PTH lik-e a c t i v i t y 
across the tumour point to the hepatic production and secretion 
of a parathyroid hormone-like humoral factor [87,90]. Recently, 
it was shown that serum PTHRP was increased in hypercalcemic HCC 
patients [72]. 
1.8 PHYSIOLOGICAL ROLE OF CYCLIC ADENOSINE MONOPHOSPHATE 
Cyclic AMP (cAMP) plays a critical role in the transmission 
of hormonal signals by functioning as a "second messenger" [91]. 
The binding of a hormone to its receptor can either enhance or 
inhibit the rate at which cAMP is produced. This is accomplished 
by altering the enzymatic activity of adenylate cyclase which 
catalyses the production of cAMP from A T P . In t u r n , the 
intracellular level of cAMP regulates the enzymatic activity of a 
protein kinase which phosphorylates other substances setting off 
a casade of cellular events which leads to the expression of the 
hormone. Hormones known to alter i n t r a c e l l u l a r cAMP l e v e l s 
include adrenaline, adrenocorticotropic hormone (ACTH),calcitonin 
, g l u c a g o n , P T H , t h y r o i d s t i m u l a t i n g h o r m o n e ( T S H ) a n d 
vasopressin . Total urinary cAMP excretion represents the sum of 
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CAMP filtered from plasma plus cAMP excreted directly into urine 
from specialized renal cells (NcAMP). NcAMP is reported to be 
the s e n s i t i v e i n d e x of p a r a t h y r o i d f u n c t i o n [ 6 1 - 6 6 ] . 
Approximately 50 per cent of urinary cAMP is generated by the 
kidney partly under the control of PTH. This NcAMP excretion can 
be suppressed by calcium infusion and stimulated by PTH in a 
dose-related manner [92] . Large dose of PTH i n f u s i o n also 
increases plasma cAMP to a small extent. However, this modest 
increase is apparently of renal o r i g i n b e c a u s e no i n c r e a s e 
occurs in anephric patients [92]• 
1.9 AIM OF THE PRESENT STUDY 
Together with serum PTH, NcAMP is a key biochemical marker 
by which HHM patients can be identified [32,61,63] . HHM syndrome 
has been extensively studied in squamous cell carcinoma of the 
lung, kidney, ovary, head or n e c k , and o e s o p h a g u s . H o w e v e r 
hypercalcemia in HCC has not aroused much attention probably 
because of the low incidence of HCC in Western countries. 
The aims of the present study are to investigate if the 
metabolism of calcium and phosphate is altered in HCC patients. 
If so, the proportion of patients who have altered metabolism and 
what is the relationship between NcAMP, plasma PTH and PTHRP that 
influence calcium metabolism. 
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CHAPTER 2 
MATERIALS M P METHODS 
2.1 PATIENTS 
Patients were recruited from Prince of Wales Hospital (PWH) 
and Queen Mary Hospital (QHH) druing 1989. Table 2. 
2.1.1 HEPATOCELLULAR CARCINOMA PATIENTS 
55 HCC patients were divided into two groups according to 
serum calcium concentrations. Four were hypercalcemic having 
serum calcium and serum albumin adjusted calcium concentrations 
above 2.6 mmol/1.They included 2 males aged 36 and 62 years and 2 
females aged 55 and 83. The remaining were normocalcemic having 
serum calcium and serum albumin adjusted calcium concentrations 
below or equal to 2.6 mmol/l.They included 42 males and 9 females 
with mean ages of 55 and 59 years , respectively. 
2.1.2 CIRRHOTIC PATIENTS 
8 cirrhotic patients, included 7 males with mean ages of 46 
and one female of 42 years, respectively. 
2.2 HEALTHY CONTROL SUBJECTS 
14 apparently healthy volunteers were recruited from the 
laboratory staff from the Department of Chemical Pathology in 
PWH and Clinical Biochemistry Unit in QMH • They included 7 males 
and 7 females with mean ages of 44 and 40 respectively. Table 2 
lists the numbers and ages of people in this study. 
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Table 2. Ages and number of patients and healthy control subject 
Mean 土 SD age 
Number of subjects in brackets 
Subjects Male Female Total 
Healthy controls 44 ±13(7) 40 ±13(7) 42 ±13(14) 
Normocalcemic 55 ±10(42) 59 土 17(9) 56 ±12(51) 
HCC 
Hypercalcemic 
HCC 33 , 62(2*) 55 , 83 (2*) 58 ±18(4) 
Cirrhosis 46 ±11(7) 42(1*) 47 ±12(8) 
* Ages of individuals 
HCC: hepatocellular carcinoma 
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2.3 COLLECTION OF BLOOD AND URINE SPECIMENS 
After an over night fast,the first urine voided after waking 
was discarded. The second urine specimen (usually after 2 hours) 
was saved. Immediately after the second voiding, 15 ml of blood 
was collected and dispensed into a plain bottle (10 ml) and an 
EDTA bottle (5 ml). Both urine and blood specimens were placed in 
ice and sent immediately to the laboratory. 
The serum was separated from the clotted blood and was used 
for the determination of calcium, phosphate,albumin, creatinine, 
ALP, PTH and PTHRP. The EDTA plasma was used for plasma cAMP 
assay (EDTA inhibits phosphodiesterase which destroys cAMP). The 
u r i n e s a m p l e w a s u s e d f o r u r i n a r y c r e a t i n i n e , c a l c i u m , 
phosphate, hydroxyproline and cAMP. 
The routine chemistries on the blood and urine specimens ( 
serum calcium, phosphate, creatinine, ALP and albumin; urinary 
calcium, phosphate and creatinine) were performed on the day of 
r e c e i p t . T h e s p e c i m e n s f o r P T H , P T H R P , c A M P a n d u r i n a r y 
hydroxyproline were aliquoted and s t o r e d at -70 deg C u n t i l 
analysis. 
2.4 METHODS 
2.4.1 ROUTINE CHEMISTRIES 
Routine chemistries were p e r f o r m e d on A m e r i c a n M o n i t o r 
Parallel Analyser (American Monitor Co, Indiancope, U.S.A) at 
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PWH. They included serum calcium, phosphate, creatinine, albumin 
ALiP, and urinary calcium, phosphate and creatinine. The serum 
calcium was was adjusted to 40 g/1 using the following formula: 
Albumin adjusted calcium concentration (mmol/l)= 
measured serum calcium concentration (mmol/l) + 
0.25 [ 40-albumin concentration(g/1)] 
2.4.2 PLASMA AND URINE CYCLIC ADENOSINE MONOPHOSPHATE 
Plasma and urine cAMP were measured by a commercial [^H] 
CYCLIC AMP radioimmunoassay kit (Diagnostic Products corporation, 
LA, California, U.S.A) . The a s s a y of cAMP is b a s e d on the 
principle of competitive protein binding using a binding protein 
purified from bovine skeletal muscle as described by Oilman [93]• 
The present kit employs a procedure described by Tovey 红 ^ 
[94].The radioactive counting was done in Beckman LS 7500 
scintillation counter (Beckman Instruments Inc, CA 92621, U.S.A). 
A data reduction program using logit-log transformation was used 
to construct a standard curve plotting the per cent bound 
against concentrations of cAMP • In this assay, urine samples are 
prediluted and plasma samples are extracted with 95 per cent 
ethanol, the diluted urines or plasma extracts are combined vrith 
tritium labelled cAMP and cAMP binding protein • Following a 90 
minutes incubation, the free (unbound) fraction is separated 
from the protein bound fraction by adsorption onto dextran-coated 
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charcoal. After centrifligation, the bound tritium labelled cAMP 
in the supernanant is counted • The amount of radioactivity is 
inversely proportional to the c o n c e n t r a t i o n of cAMP in the 
sample. 
Three commercial urine controls w e r e o b t a i n e d from Ciba 
corning (Ciba corning Diagnostic Corp;Irvine,CA 92714,U.S.A).They 
were: 
Gilford urine I (lot 090603) 
Gilford urine II (lot 095601) 
Corning urine II(lot 095703) 
Tlie scintillation cocktail was prepared by dissolving 4.0 g 
2,5-diphenyl oxazole (PPO) and 0.267 g p - b i s { 2 - ( 5 - p h e n y l 
oxazolyl)-benzene) (POPOP) in 1 litre of xylene (Merck; F.R.G) 
and 333 ml Triton X - 1 0 0 . P P O , P O P O P and T r i t o n X - 1 0 0 w e r e 
obtained from Sigma (Sigma; St Louis,HO,U.S.A) • The optimal 
volume of scintillation cocktail used in each vial was 12.5 ml 
and counting time was 5 minutes. 
W i t h i n - r u n i m p r e c i s i o n w a s a s s e s s e d b y r u n n i n g f i v e 
replicates for each commercial urine control in a single run. 
Between-run imprecision was assessed by running the three urine 
controls in seven runs. 
Accuracy was assessed by comparing the mean results of the 
three urine controls in seven runs with their assigned values. A 
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recovery experiment was also done by adding 0.4 ml of stock cAMP 
standard to 0.6 ml diluted Gilford Urine I and II and were run 
in duplicates. 
2.4.3 NEPHROGENOUS CYCLIC ADENOSINE MONOPHOSPHATE AND TOTAL 
URINARY CYCLIC ADENOSINE MONOPOSPHATE / 100 ML GLOMERULAR FILTRATE 
Total urinary cAMP excretion r e p r e s e n t s the sum of cAM? 
filtered from plasma plus cAMP excreted directly into urine from 
specialized renal cells (NcAMP) [91]. To calculate NcAMP,both 
plasma and urine cAMP measurements are necessary as well as serum 
and urine creatinine. The method used for calculating NcAMP is 
given below: 
A . Expresss the urinary concentration of cAMP as nmol cAMP per 
100 ml of urine. 
B . Divide nmol cAMP/100 ml urine by the c o n c e n t r a t i o n of 
urinary creatinine,i.e. 
nmol cAMP /lOO ml urine 
= n m o l cAMP/mmol creatinine 
mmol creatinine / 100 ml urine 
C. Calculate the total nmol of c A M P e x c r e t e d per 100 ml 
glomerular filtrate by multiplying the value obtained in B by 
plasma creatinine concentration,i.e. 
nmol cAMP/ mmol creatinine x mmol creatinine/lOOml plasma 
= n m o l cAMP /lOO ml glomerular filtrate 
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D. Express the plasma concentration of cAMP as nmol cAMP/100 
ml plasma. This is the filtered cAMP. 
E . Calculate NcAMP by subtracting the filtered cAMP (result D) 
from ther total urinary e x c r e t i o n of cAMP per 100 ml 
glomerular filtrate {result C〉， i.e. 
NcAMP (nmol/100 ml glomerular filtrate ) = 
Total urinary cAMP (nmol cAMP/100 ml g l o m e r u l a r f i l t r a t e ) -
filtered cAMP (nmol cAMP /lOO ml plasma) 
2.4.4 TOTAL URINARY CYCLIC ADENOSINE MONOPHOSPHATE : CREATININE 
RATIO 
Total urinary cAMP : creatinine ratio (nmol/mmol creatinine) 
was calculated by dividing urine cAMP by uirinairy creatinine. 
2.4.5 COMPONENTS OF HYPERCALCEMIA 
The contributions by renal c a l c i u m r e a b s o r p t i o n , b o n e 
resorption and renal function to hypercalcemia in HCC patients 
were calculated using the method described by Nordin [95]. This 
method is based on the relationship between fasting serum calcium 
concentration and urinary c a l c i u m e x c r e t i o n per l i t r e of 
glomerular filtrate. At a particulai: level of urinary calcium 
excretion; the plasma calcium concentration is compared with that 
in the reference line, the distance of observed datum point in 
36 
plasma calcium from the reference line represents that component 
of hypercalcemia due to tubular r e a b s o r p t i o n . If the p l a s m a 
creatinine is over 0.1 mmol/l, moving down the reference line 
from the observed urinary calcium excretion to what it would be 
at plasma 
creatinine of 0.1 mmol/l. The distance of observed 
datum in plasma calcium from the reference line represents that 
component of hypercalcemia due to low glomerular filtration rate. 
The rest of hypercalcemia is due to bone resorptipon. 
2.4.6 URINARY HYDROXYPROLINS : CREATININE RATIO 
Urinary hydroxyproline was a s s a y e d by a m a n u a l m e t h o d 
described by Prockop [96]• In this method, urinary hydroxyproline 
is oxidized to a pyrrole which is then measured colorimetrically 
by reacting with p - d i m e t h y l a m i n o b e n z a l d e h y d e . The r e s u l t is 
expressed as hydroxyproline : c r e a t i n i n e r a t i o ( u m o l / m m o l 
creatinine). At concentration of 78 and 507 umol/1, the between-
run coefficients of variation w e r e 14.5 and 13.5 per cent 
respectively. The information on within-run imprecision was not 
available. 
2.4.7 RENAL PHOSPHATE THRESHOLD 
Renal phosphate threshold expressed as maximum excretion of 
phosphate in mmol/l of g l o m e r u l a r f i l t r a t e ( T M P / G F R ) was 
calculated from a nomogram described by Bijvoet [97]. In this 
nomogram, tubular reabsorption of phosphate (TRP) is derived from 
phosphate and creatinine clearance. A stright line through the 
appropriate value of plasma phosphate and TRP passes through the 
corresponding value of TMP/GFR in the nomogram. 
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2.4.8 SERUM PARATHYROID HORMONE 
Serum parathyroid hormone was m e a s u r e d by a c o m m e r c i a l 
radioimmunoassay kit, ALLEGRO INTACT PTH (Nichols Institute, San 
Juan Capistrano,CA 92675,U.S.A). The sensitivity of the assay is 
1 pg/ml. At concentration of 40 and 266 pg/ml, the within-run 
coefficients of variation were 3.4 and 1.8 per cent respectively; 
the between-run coefficients of variation were 5.6 and 6.1 per 
cent respectively. This assay is a two -site iiamunoradiometric 
assay (IRMA) for the measurement of intact PTH • Two different 
goat polyclonal antibodies to human PTH are used. One antibody 
which is specific to the mid-region and C-terminal of hPTH(39-84) 
is immobilized onto plastic beads. The other antibody which is 
iodine 125 labelled is specific to the N-terminal of hPTH{l-34). 
The sample containing PTH is incubated with these two antibodies 
to form a "sandwich" complex. At the end of 24 hours incubation, 
t h e b e a d is w a s h e d to r e m o v e t h e u n b o u n d c o m p o n e n t s . 
Radioactivity bound to the s o l i d p h a s e is m e a s u r e d . T h e 
radioactivity is directly proportional to the amount of intact 
hPTH(l-84) in the sample. 
2.4.9 SERUM PARATHYROID HORMONE-RELATED PEPTIDE 
Serum PTHRP was measured by a commercial radioiirmmnoassay, 
PTH RELATED PEPTIDE (Immuno Technology Service Production,B.V. 
Netherlands) in the Department of Medicine, University of Hong 
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Kong. The sensitivity of the kit is 2 pg/ml. At concentration of 
11 and 50 pg/ml, the within-run coefficients of variation were 10 
and 5 per cent. The information on between-run precision was 
not available. In this assay, serum samples are extracted by 
Waters seppark C18 catridge. The e x t r a c t e d s a m p l e s are then 
combined with PTHRP antiserum and are incubated for 24 hours . 
Then iodine 125 labelled PTHRP is added . Following a 18 hours 
incubation, separation of free (unbound) P T H R P is m a d e by 
centrigf ligation and aspiration of the supernatant. The bound 
fraction in the pellet is counted in a g a m m a c o u n t e r . The 
radioactivity is inversely proportional to the amount of PTHRP 
in the sample. 
2.5 STATISTICAL ANALYSIS 
T h e E P I S T A T s t a t i s t i c a l p a c k a g e ( R o u n d R o c k , T e x a s 
78664,U.S.A) was used for data a n a l y s i s . A l l r e s u l t s w e r e 
reported as mean + SD. The significance of difference between two 
study groups was analysed by Wilcoxon rank sum test or unpaired 
Student's t test as appropriate. Linear regression analysis was 




This chapter describes the results for method validation for 
CAMP assay as well as results for the HCC patients, cirrhotic 
patients and healthy control subjects. 
3.1 METHOD VALIDATION FOR CYCLIC ADENOSINE MONOPHOSPHATE ASSAY 
Owing to the limited supply of reagent kits,a full method 
validation for cAMP assay was not performed • Parameters studied 
w e r e w i t h i n - r u n a n d b e t w e e n - r u n p r e c i s i o n , a c c u r a c y by 
comparision with assigned values in commercial control urines and 
recovery study. 
STANDARD CURVE OF THE CYCLIC ADENOSINE MONOPHOSPHATE ASSAY 
The standard curve of the a s s a y was c o n s t r u c t e d from 6 
standards by plotting per cent bound against concentration using 
logit-log transformation. Results for the standards in seven runs 
were shown in Table 3. A typical standard curve is shown in 
Figure 1. The coefficient of v a r i a t i o n of per cent b o u n d 
increases with concentration in the standards from 3.7 to 17.9 
per cent. 
ko 
Table 3. Mean % bound of standards of cAMP 
Standards Concentration Mean % bound (SD) C.V. of % bound 
Number of runs= 7 (pmol/lOOul) ( % ) 
1 0.11 97.4 (3.6) 3.7 
2 0.33 84,3 (6.9) 8.2 
3 1.00 56.1 (7.1) 12.7 
4 3.00 29.9 (5.3) 17.7 
5 9.00 13.5 (2.4) 17.8 
6 27.00 5.6 (1.0) 17.9 
cAMP :cyclic adenosine monophosphate 
C.V. :coefficient of variation 
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3.1.2 RESULTS OF IMPRECISION STUDY 
The results of imprecision study are sumarized in Table 4. 
The within—run coefficient of variation varied from 1.3 to 3.5 
per cent ,and the between-run coefficient of variation varied 
from 16.3 to 17.4 per cent. 
3.1.3 RESULTS OF ACCURACY STUDY 
Results of accuracy study are shown in Table 5. The means 
and medians of Gilford Urine I and II agreed closely with their 
assigned values, with bias of -8.1 and +2.7 per cent. However, a 
large positive bias of +25.8 per cent was observed in Corning 
Urine 11, and yet the median of it was still within the assigned 
range. An outlier of 25 umol/1 in Corning Urine II was observed. 
If the outlier was deleted, the bias was still +20 per cent • 
Another approach to assess accuracy is by recovery study. A 
recovery experiment was done by adding 0.4 ml of stock cAMP 
standard (27 pmol/lOOul) to 0.6 ml G i l f o r d U r i n e I and II 
(prediluted 100 folds) and were run in duplicates. Results are 
shown in Table 6. The mean recovery observed was 90 per cent. 
Table 4. Precision of cMP assay 
Ccxnnercial urine Mean (SD ) C.V. 
controls (nmol/l) ( % ) 
Within-run {n=5) 
Gilford Urine I 7.62 (0.24) 3.1 
Gilford Urine II 17.38 (0.22) 1.3 
Coming Urine II 24.20 (0.84) 3.5 
Between-run (n=7) 
Gilford Urine I 6.80 (1.11) 16.3 
Gilford Urine II 18.90 (3.28) 17.4 
Coming Urine 11 20.00 (3.25) 16.3 
cAMP :cYt:lic adenosine monophosphate 
C.V. :coefficient of variation 
« 
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Table 5. Comparison of experimental values with the 
the assigned values for the three coifnercial urine controls 
Gilford Urine I Gilford Urine II Corning Urine II 
Assigned values* 7.4 土 2.5 18.4 土 6.0 15.9 ±4.0 
Mean experimental 6.8 土 2.2 18.9 土 6.6 20.5 士 6.5 
values (mean±2SD)* 
Median* 6.8 17.6 18.5 
% Bias -8.1 +2.7 +25.8 
* concentration in umol/l 
- • • 
Table 6. Recovery study by adding commercial urine 
controls with cAMP standard 
Commercial Urine Expected values Observed values Recovery 
controls (umol/l) (umol/1) (%) 
Gilford Urine I* 14.6 13.0 89.0 
Gilford Urine II* 21.4 19.0 90.5 




3.2 RESULTS OF HYPERCALCEMIC AND NORMOCALCSHIC HEPATOCELLULAR 
CARCINOMA PATIENTS, CIRRHOTIC PATIENTS, AND HEALTHY 
CONTROL SUBJECTS 
This section describes the r e s u l t s of h y p e r c a l c e m i c and 
normocalcemic HCC patients, c i r r h o t i c p a t i e n t s and h e a l t h y 
control subjects. Results of hypercalcemic HCC patients are 
compared with those of normocalcemic HCC patients, cirrhotic 
patients and healthy control subjects. Results of normocalcemic 
HCC patients and cirrhotic patients are also compared with those 
of the healthy control subjects. Comparison of results between 
males and females are made in the normocalcemic HCC patients and 
healthy controls . 
3.2.1. RESULTS OF SERUM CALCIUM, ALBUMIN ADJUSTED CALCIUM, SERUM 
ALBUMIN AND SERUM ALKALINE PHOSPHATASE 
The results of serum calcium, albumin adjusted calcium, 
serum albumin and serum ALP are summarized in Table 7.There was 
no significant difference in serum calcium concentration between 
males and females in normocalcemic HCC patients and in healthy 
control subjects.Normocalcemic HCC and cirrhotic patients showed 
comparable results the h e a l t h y c o n t r o l s u b j e c t s . S e r u m 
Table 7. Results of serum calcium, alimin adjusted caidum, 
senm albumin and senim alkaline phosphatase 
Results as nean (SD) 
Unit and reference range in bracket under test 
TEST HEALTHY CI?纖IS K M X M J M C HYPERCALCZMC 
CCMROLS HCC HCC 
male/female 7/7 7/1 ^2/3 2/, 
total 14 8 51 , 
Serum calcium 
(鹏 1/1; 2.I3-2.51) total 2.34 (0.10)+ 2.24 (0.13” 2.25(0.14)” 3.15 (0.24广 
Alburaiii adjusted male 2.13 (0.13)本 
caidunL大 female 2.25 (0.05) 
(励1/1; 2.13-2.51) total 2.20 (0.11) 2.26 (0.16广 2.35 (0.14) ^  + 3,29 (0.21)让 
Serum albumin 
(g/1; 36-48) total 46 (3” 39 (9” 36 35.⑶ ad 
Serum alkaline male 75 (21) t 
phosphatase feoale. 49 (U) 
(IU/1;务 13S) total 62 (21) 84 (31丫 251 (180)" 2.92 (193)这“ 
n =7 
HCC : Hepatocellular:. cardjKnia 
NS : No significant difference; 
* • Albumin adjusted calcium concentratiai (inrDl/l)= 
roeasmred serum calcium concentration (iniol/l) + 
0.025 X [ 40- albumin concentration ( g/1)] 
+ : NS, inale vs. female; 
；:Significant difference ( p< 0.05 ), male vs. feniale; 
a ： Significant difference ( p< 0.001) vs. healthy controls-
^ ： Significant difference ( p< 0.001) vs, n o m x a l c ^ c HCC and cirrhotic patients 
^ . Sigmiicant Qiiierence ( p< 0.05) vs. healthv controls; 
d : NS, vs. nonnocalcenic HCC and cirrhotic patients; 
e : NS, vs. healthy controls. ‘ 
f : NS, vs. normocalcsniic HCC patients; 
g : Significant dirierence ( P< Q.OI) VS. cirrhotic patients;.. 
L3 
calcium concentration was higher in hypercalcemic HCC patients 
(3.15 + 0.24 mmol/l compared to 2.25 + 0.14 in normocalcemic HCC 
patients; 2.24 + 0.13 in c i r r h o t i c p a t i e n t s ; 2.34 + 0.10 in 
healthy control subjects). The distribution of serum calcium in 
the three patient groups and in the healthy controls is shown in 
figure 2. 
In the healthy control g r o u p , f e m a l e s had s i g n i f i c a n t l y 
higher serum albumin adjusted calcium concentrations than males 
(2.25 + 0.05 mmol/l compared to 2.13 + 0.13, p<0.05), and there 
was no significant difference in serum albumin adjusted calcium 
levels between males and females in the normocalcemic HCC group. 
Normocalcemic HCC and cirrhotic p a t i e n t s s h o w e d c o m p a r a b l e 
I 
results with healthy controls subjects. Serum albumin adjusted 
calcium concentration was higher in hypercalcemic HCC patients , 
(3.29 + 0.21 mmol/l compared to 2.35 + 0.14 in normocalcemic HCC 
patients; 2.26 + 0.16 in c i r r h o t i c p a t i e n t s ; 2.20 + 0 . 1 1 in 
healthy control subjects). 
There was no significant d i f f e r e n c e in s e r u m a l b u m i n 
concentration between males and females in normocalcemic HCC 
patients and in healthy control gruop.No significant differences 
w e r e o b s e r v e d in s e r u m a l b u m i n c o n c e n t r a t i o n b e t w e e n 
hypercalcemic HCC,normocalcemic HCC and cirrhotic patients.Serum 
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FIG 2 . Distribution of serum calcium concentration in 
hypercalcemic HCC patients, normocalcemic HCC patients, 
cirrhotic patients and healthy controls 
HCC: hepatocellular carcinoma 
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in the healthy control s u b j e c t s (46 + 3 g / 1 in the h e a l t h y 
controls compared to 35 + 3 in hypercalcemic HCC patients; 3 6 + 6 
in normocalcemic HCC patients; 39 + 9 in cirrhotic patients )• 
In the healthy control group, females had lower serum ALP 
levels than males (49 + 11 IU/1 compared to 72 + 21, p<0.05). No 
significant difference was observed in serum ALP level between 
m a l e s a n d f e m a l e s in t h e n o r m o c a l c e m i c H C C p a t i e n t s . No 
s i g n i f i c a n t differences were o b s e r v e d in s e r u m ALP b e t w e e n 
hypercalcemic and normocalcemic HCC patients.Serim ALP level 
was higher in the HCC patients than in healthy control subjects 
and cirrhotic patients (62 + 21 IU/1 in the healthy controls ； 84 
1 31 iri cirrhotic patients compared to 232 + 193 in hypercalcemic 
HCC patients; 251 j： 180 in normocalcemic HCC patients ； ) . 
3.2.2 RESULTS OF SERUM PHOSPHATE, RENAL PHOSPHATE THRESHOLD 
AND SERUM PARATHYROID HORMONE 
The results of serum phosphate, renal phosphate threshold 
(TMP/GFR) and serum parathyroid hormone are summarized in Table 
8. 
There was no significant d i f f e r e n c e b e t w e e n m a l e s and 
females in serum phosphate concentration in the healthy control 
group. Males had higher values than females in the normocalcemic 
HCC group (1.15 + 0.14 mmol/1 compared to 1.00 + 0.3, p< 0.05). 
There was no significant difference in phosphate concentration 
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Table 8. Results of serum phosphate, renal phosphate threshold 
and serum parathyroid hormone 
Results as mean (SD) 
Unit and reference range under test 
TEST HEALTHY CIRRHOSIS lOMOCALCEMIC HYPERCALCEMIC 
CONTROLS HCC HCC 
male/female 7/7 7/1 42/9 2/2 
total 14 8 51 4 
male 1.15 (0.14)^ 
Serum phosphate female 1.00 (0.30) 
(rmol/1； 0.81-1.4) total 1.11 (0.13) ^  0.91 (0.14” 1.13 (0.19) ^  0.81 (0.05)"^ 
Renal phosphate 
threshold* ^^ 
(ranol/l GF; 0.8-1.35) total 1.01 (0.22)+ 0.89 (0.21)^ 1.03 ( 0 . 2 8 ) 0 . 5 1 (0.10)^ 
n=50 
Serum PTH* 
(pg/ml； 10-50) total 20.4 (7.9)+ 23.6 (10.3广 11.8 (10.8广+ 2.1 (1.2) 
HCC ： Hepatocellular carcinoma; PTH : Parathyroid hormone; 
GF : Glomerular filtrate; NS : No significant difference; 
* ； Wilcoxon rank sum test; 
+ : NS, male vs. female; 
t : Significant difference ( p< 0.05 ), male vs. female; 
a : Significant difference ( p< 0.001) vs. healthy controls; 
b : Significant difference ( p< 0.05) vs.normocalcemic HCC and cirrhotic patients; 
c : Significant difference ( p< 0.001) vs. nonnocalceinic HCC patients; 
d : Significant difference ( p< 0.01) vs. cirrhotic patients; 
e : Significant difference ( p< 0.005) vs. normocalcemic HCC patients; 
f : Significant difference ( p< 0.05) vs. cirrhotic patients; 
g ： Significant difference ( p< 0.005) vs. healthy controls; 
h : NS, vs. healthy controls. 
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between normocalcemic HCC patients and healthy control subjects. 
Cirrhotic patients had lower serum phosphate concentration than 
healthy control subjects (0.91 + 0.14 mmol/l compared to 1.11 + 
0.13, p<0.005 ). Serum phosphate c o n c e n t r a t i o n was lower in 
hypercalcemic HCC patients (0,81 + 0.05 mmol/l compared to 1.13 + 
0.19 in normocalcemic HCC; 0.91 + 0.14 in cirrhotic patients; 
1.11 + 0.13 in healthy controls subjuect ). The distribution of 
serum phosphate in the three p a t i e n t g r o u p s and in h e a l t h y 
controls is shown in Figure 3. 
There was no significant difference in TMP/GFR between males 
and females in normocalcemic HCC patients and in healthy control 
subjects.Normocalcemic HCC and cirrhotic patients had comparable 
results with healthy control subjects. Renal phosphate threshold 
(TMP/GFR) was lower in hypercalcemic HCC patients ( 0.51 + 0.1 
m m o l / l g l o m e r u l a r f i l t r a t e c o m p a r e d to 1 . 0 3 + 0 . 2 8 in 
normocalcemic HCC patients; 0.89 + 0.21 in cirrhotic patients,. 
1.01 + 0,22 in healthy control subjects ). There are 2 patients 
in the normocalcemic HCC group who had suppressed TMP/GFR ( 0.40, 
0.35 mmol/l)； one of whom had increased serum PTHRP concentration 
( o v e r 400 pg/ml) , the remaining one had s u p p r e s s e d serum 
phosphate (0.35 mmol/l) for u n k n o w n r e a s o n s . D e s p i t e t h e s e 
changes, both patients had normal NcAMP excretion. There was 
another patient in the normocalcemic HCC group who had highly 
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urinary excretion of .phosphate (0.2 mmol/l compared to 19.6 + 
12.6 in his group). This TMP/GFR v a l u e was d i s c a r d e d , the 
distribution of TMP/GFR in the three patient groups and in the 
healthy control is shown in F i g u r e 4 . 
T h e r e w a s no s i g n i f i c a n t d i f f e r e n c e in s e r u m P T H 
concentration between males and females in the normocalcemic HCC 
patients and in the healthy c o n t r o l s . N o r m o c a l c e m i c HCC and 
cirrhotic patients showed comparable results with healthy control 
subjects.Serum PTH concentration was suppressed in hypercalcemic 
HCC patients (2.1 + 1.2 p g / m l c o m p a r e d to 11.8 + 10.8 in 
normocalcemic HCC patients; 23.6 ± 10.3 in cirrhotic patients; :\ 
20.4 t 7.9 in healthy control subjects). The distribution of 
serum PTH in the three patient g r o u p s and in the h e a l t h y ’ 
controls is shown in Figure 5. ： 
3.2.3 RESULTS OF PLASMA CYCLIC ADENOSINE MONOPHOSPHATE 
The results of plasma cAMP are shown Table 9. 
T h e r e w a s no s i g n i f i c a n t d i f f e r e n c e in p l a s m a c A M P 
concentration between males and females in the healthy controls ; 
but males had higher values than females in the normocalcemic HCC 
patients ( 8.3 + 2.4 nmol/1 compared to 6.1 + 2.0 ,p< 
0.05).Normocalcemic HCC patients and cirrhotic patients had 
c o m p a r a b l e p l a s m a c A M P l e v e l s w i t h h e a l t h y c o n t r o l 
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Table 9. Results of plasma c M P 
Results as mean (SD) 
Unit in bracket under test 
TEST HEALTHY CIRRHOSIS NCMfOCALCEMIC HYPERCALCEMIC 
CONTROLS HCC HCC 
male/fomale 7/7 4/1 41/9 2/2 
total 14 5 50 4 
male 8.3 (2.4) ^  
Plasma cAMP* female 6.1 (2.0) 
(nmol/l) total 5.0 (3.1)+ 5.8 (2.9) ^  7.9 (2.5) b 6.8 (2.9)^ 
cAMP : Cyclic adenosine monophosphate; 
HCC : Hepatocellular carcinoma; 
NS : No significant difference; 
* : Wilcaxon rank sum test; 
+ : NS, male vs. female; 
t ： Significant difference ( p< 0.05 ), male vs. female; 
a : NS, vs. healthy controls, normocalcemic HCC and cirrhotic patients; 
b : NS, vs. healthy controls. 
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significantly different from n o r m o c a l c e m i c HCC p a t i e n t s , 
c i r r h o t i c p a t i e n t s and h e a l t h y c o n t r o l s u b j e c t s . T h e 
distribution of plasma cAMP in the three patient groups and in 
the healthy controls is shown in Figure 6. 
3.2.4 RESULTS OF NEPHROGENOUS CYCLIC ADENOSINE MONOPHOSPHATE, 
TOTAL URINARY CYCLIC ADENOSINE MONOPHOSPHATE / 100 ML GLOMERULAR 
FILTRATE AND TOTAL URINARY CYCLIC ADENOSINE MONOPHOSPHATE : 
CREATININE RATIO 
The results of NcAMP,total urinary cAMP /lOO ml glomerular 
filtratre and total urinary cAMP : creatinine ratio are shown in 
Table 10. 
There was no significant difference in NcAMP between males 
and females in normocalcemic HCC patients and in the healthy 
controls.Normocalcemic HCC and c i r r h o t i c p a t i e n t s s h o w e d 
comparable results with healthy control subjects.Hypercalcemic 
HCC patients had significantly elevated NcAMP ( 10.21 + 1.70 
nmol/100 ml glomerular filtrate c o m p a r e d to 2.13 + 1.10 in 
normocalcemic HCC patients; 1.67 + 0.18 in cirrhotic patients; 
2.42 + 1.11 in healthy control subjects ) • The distribution of 
NcAMP in the three patient groups and in the healthy controls is 
shown in Figure 7. 
59 
2 4 一 
之 2 2 _ 
〇 
^ 2 0 _ <£ 
K 
H 1 P 
S ‘‘ 一 0 
S 1 6 -
8 0 
I < … 
^ § 12 - m 
< Z d 
g - Efc • m ° 
^ 卜 ° • ； p b 
4 - m • ffl 口 
卜 a ° 
D , 
Healthy Cirrhoais Normocalcemic Hypercalcemic 
Controls ‘ HCC HCC 
n= n= 5 n= k 
FIG 6. Distribution of plasma cAMP concentration in 
hypercalcemic HCC patients, nor.ocalce.ic HCC patients, 
cirrhotic patients and healthy controls 
HCC : hepatocellular carcinoma; 
CAMP: cyclic adenosine monophosphate 
60 
Table 10. Results of NcMP, UcAMP/100 ml GF, UcAMP:creatinine ratio 
Results as mean (SD) 
Unit and reference range in bracket under test 
TEST HEALTHY CIRRHOSIS NORMOCALCEMIC HYPERCALCEMIC 
CONTROLS HCC HCC 
male/female 7/7 4/1 41/9 2/2 
total 14 5 50 4 
NcAMP* 
(nmol/lOOml GF; + ^ 
< 4.52§) total 2.42 (1.11)+ 1.67 (0.18)' 2.13(1.10”+ 10.21 (1.7) 
UcMP/100 ml GF* male 2.42 (0.52)* 
(nmol/lOO ml GF; fomale 3,42 (1.09) 
< 5.25§ ) total 2.92 (0.99) 2.25 (0.41广 2.92 (1.11广+ 10.89 (1.7)"^ 
UcAMP:creatinine 
ratio* male 255 (60) ^  
(nmol/mmol creatinine; female 460 (199) 
< 485§ ) total 358 (179) 273 (42)。 361(142)。+ 1373 (428)油 
NcAMP : Nephrogenous cyclic adenosine monophosphate; 
UcAMP : Total urinary cyclic adenosine monophosphate; 
HCC : Hepatocellular carcinoma; 
NS : No significant difference; 
GF : Glotnerular filtrate; 
* : Wilcoxon rank sum test; 
+ : NS, male vs. female; 
本 :Significant difference ( p< 0.05 ), male vs. female; 
§ : Reference 66; 
a : Significant difference ( p< 0.001) vs. healthy controls and nomocalcemic HCC patients; 
b : Significant difference { p< 0.05) vs. cirrhotic patients; 
c : NS,vs. healthy controls. 
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In the healthy control group,males had lower total urinary 
c A M P / 1 0 0 ml g l o m e r u l a r f i l t r a t e t h a n f e m a l e s (2.42 + 0 . 5 2 
nmol/100 ml glomerular filtrate compared to 3.42 + 1.09, p<0.05). 
There was no significant difference in total urinary cAMP /lOO ml 
g l o m e r u l a r f i l t r a t e b e t w e e n m a l e s a n d f e m a l e s in t h e 
n o r m o c a l c e m i c HCC p a t i e n t s • N o r m o c a l c e m i c H C C a n d c i r r h o t i c 
p a t i e n t s showed c o m p a r a b l e r e s u l t s w i t h t h e h e a l t h y c o n t r o l 
subjects. Total urinary cAMP / 100 ml glomerular filtrate was 
significantly elevated in the hypercalcemic HCC patients (10.89 + 
1.70 nmol/lOOml glomerular filtrate compared to 2.92 + 1.11 in 
normocalcemic HCC patients; 2.25 + 0.41 in cirrhotic patients ; 
2.92 ± 0.99 in healthy control subjects).The distribution of 
total urinary cAMP /lOO ml glomerular filtrate in the three 
patient groups and in the healthy controls is shown in figure 8. 
Total urinary cAMP/100 ml glomerular filtrate correlated very 
well with NcAMP ( r=0.991, p<0.000001,slope =0.99,n=73; figure 
9). 
In the healthy control group, males had lower total urinary 
cAMP:creatinine ratio than females (255 + 60 nmol/mmol creatinine 
compared to 460 + 199, p<0.05). The was no significant difference 
in urinary cAMP:creatinine ratio between males and females in the 
normocalcemic HCC group.Normocalcemic HCC and cirrhotic patients 
showed comparable results with the healthy control group.Total 
urinary cAMP:creatinine ratio was elevated in hypercalcemic HCC 
patients ( 1373 + 428 nmol/mmol creatinine compared to 361 + 142 
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in the normocalcemic HCC patients; 273 + 42 in the cirrhotic 
patients; 358 + 179 in the h e a l t h y c o n t r o l s u b j e c t s ) . T h e 
distribution of total urinary cAMPrcreatinine ratio in the three 
patient groups and in the healthy controls is shown in Figure 
10.Total urinary cAMPrcreatinine ratio correlated well with NcAMP 
(r=0.914,p<0.000001, slope =124,n=73, fig 11). 
Table 11 summarizes the results of plasma cAMP,NcAMP, total 
urinary cAMP/100 ml glomerular f i l t r a t e and t o t a l u r i n a r y 
cAMPicreatinine ratio in this s t u d y in c o m p a r i s o n w i t h the 
findings of other author. 
3.2.5 RESULTS OF URINARY CALCIUM:CREATININE RATIO AND URINARY 
HYDROXYPROLINE:CREATININE RATIO 
The results of urinary calcium:creatinine ratio and urinary 
hydroxyprolinercreatinine ratio are shown in Table 12. 
T h e r e w a s no s i g n i f i c a n t d i f f e r e n c e in u r i n a r y 
calcium:creatinine ratio between males and females in the healthy 
c o n t r o l g r o u p a n d in t h e n o r m o c a l c e m i c H C C p a t i e n t s . 
Normocalcemic HCC and cirrhotic patients had comparable results 
with the healthy control subjects.Hypercalcemic HCC patients had 
higher urinary calcium:creatinine ratio (2.01 +0.54 mmol/mmol 
creatinine compared to 0.21 + 0 . 1 9 in the n o r m o c a l c e m i c HCC 
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Table 11. Results of plasma cAMP, total urinary cyclic adenosine monophosphate ， 
urinary cAMP •  creatinine ratio conpared with 
findings of other authors 
Results as mean (SD) 
Unit in bracket under test 
Subjects N Plasma cAMP NcAMP UcAMP/lOOml GF UcAMP« creatinine 
ratio 
(nitol/100 ml) (nmol/lCOml GF)' (nmol/lOOml GF) (nmol/rnrrol creatinine) 
HEALTHY COTOOLS 
-mis study 14 0.50 (0.31) 2.42 (1.11) 2.92 (0.99) 358 (179) 
Rude et al 18来 1.80 (0.41) 2.20 (1.20) 3.86 (1.30) NA 
Stuart et al 16 十 0.81 (0.47) 1.80 (1.36) 2.59 (1.33) 226 (130) 
HYPERCi^IiCEMrC 
CANCER 
(HCC) I M S study 4 0.68 (0.29) 10.21 (1.70) 10.89 (1.70) 1372 (428) 
Rude et al 91来 3.30 (1.72) 5.70 (7.60) 8.9 (7.9) NA 
Stuart et al 15+ 2,20 (1.10) 7.93 (9.47) 9.23 (10.20) 1044 (1154) 
NORMXALCEMIC 
CANCER 
(HCC) This study 51 0.79 (0.25) 2.13 (1.10) 2.92 (1.11) 361 (142) 
Rude et al 15* 2.20 (0.85) 4.20 (2.10) 6.30 (2.20) NA 
Stuart et al 3+ 1.61 (0.29) 1.00 (0.70) 2.70 (2.20) 305 (249) 
cAMP : cyclic adoiosiiie nonophosphate 
UcAMP : total urinary cyclic adenosine fnonophosphate 
NcAMP : nei^irogenous cyclic adenosine monopk^sphate 
NA : not available 
GF : glonemlar filtrate 
HCC : hepatocellular carcinoma 
来 reference 61 
+ reference 66 
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Table 12. Results of urinary calcium : creatinine ratio and 
hydroxyproline : creatinine ratio 
Results as mean (SD) 
Unit and reference range in bracket under test 
TEST HEALTHY CIRRHOSIS NORMOCALCEMIC HYPERCALCEMIC 
C O m O L S HCC HCC 
male/female 7/7 7/1 42/9 2/2 








below 30本） total 10.9 (1.5)' 15.3 (13.4)^ 16.2 (10.7)'^' 58.0 (28.4)'' 
HCC : Hepatocellular carcinona; 
UCa : Urinary calcium; 
UOHP : Urinary hydroxyproline; 
NS : No significant difference; 
* : Wilcoxon rank sum test; 
+ : NS, male vs. female; 
t : reference 22; 
a : Significant difference { p< 0.001) vs. healthy controls and normocalcemic HCC patients; 
b : Significant difference ( p< 0.005) vs. cirrhotic patients; 
c : Significant difference ( p< 0.05) vs. cirrhotic patients; 
d : NS, vs. healthy controls. 
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- . . 
the healthy control s u b j e c t s ) . T h e d i s t r i b u t i o n of u r i n a r y 
calciumrcreatinine ratio in the three patient groups and in the 
healthy controls is shown in Figure 12. 
T h e r e w a s no s i g n i f i c a n t d i f f e r e n c e in u r i n a r y 
hydroxyproline icreatinine ratio between males and females in the 
h e a l t h y c o n t r o l g r o u p a n d in t h e n o r m o c a l c e m i c H C C 
patients.Normocalcemic HCC and c i r r h o t i c p a t i e n t s s h o w e d 
comparable results with the healthy control subjects. Urinary 
hydroxyproline :creatinine ratio was higher in the hypercalcemic 
HCC patients (58.0 + 28.4 umol/mraol creatinine compared to 16.2 + 
10.7 in the normocalcemic HCC p a t i e n t s ; 15.3 + 13.4 in the 
c i r r h o t i c p a t i e n t s ; 1 0 . 9 + 1 . 5 in t h e h e a l t h y c o n t r o l 
subjects).The distribution of urinary hydroxyproline: creatinine 
ratio in the three patient groups and in the healthy controls is 
shown in figure 13. 
3.2.6 FACTORS CONTRIBUTING TO HYPERCALCEMIA IN HEPATOCELLULAR 
CARCINOMA PATIENTS 
The results on the contributions of renal tubular calcium 
r e a b s o r p t i o n , b o n e r e s o r p t i o n and r e n a l f u n c t i o n to t h e 
hypercalcemia in HCC patients is shown in Table 13. 
Of the 4 hypercalcemic HCC patients, 3 had bone resorption 
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Table 13. Contribution by renal tubular reabsorption , GFR, 
— bone resorption to hypercalcemia in Hcc'patients 
nCC patients reahso^tion resorption concentration adjusted calcium 
— ^ ⑷ ⑷ (mmol/1) (mmol/1) 
No'l -5.2 +2.6 +102.6 3.26 3.44 
恥.2 -62.5 +25.0 +137.5 2.90 3.15 
贴.3 +85.0 -23.0 +38.0 3.50 3.55 
^ +22.0 -58.0 +136.0 2.95 3.03 
Mean +9.8 -13.4 +103.5 ~ ~ 
Median +8.4 -10.2 +119.3 
SI) 61.3 35.6 46.6 
HCC: hepatocellular carcinoma; 
GFR: glonerular filtration rate 
a? 
reabsorption as the major factor. Reduced renal function was not 
a major contributing factor contributing to hypercalcemia in 
these patients.The patient with the tubular reabsorption as the 
major factor of hypercalcemia had the highest serum calcium and 
albumin adjusted calcium concentrations. 
3.2,7 RESULTS OF SERUM PARATHYROID HORMONE-RELATED PEPTIDE 
The results of serum PTHRP alone with other parameters 
studied are shown in Table 14. Serum PTHRP was performed on 13 
normocalcemic HCC patients, 2 h y p e r c a l c e m i c HCC p a t i e n t s , 1 
c i r r h o t i c p a t i e n t a n d 1 h e a l t h y c o n t r o l . S e r u m P T H R P 
concentration was highly increased in the 2 hypercalcemic HCC 
patients- The single healthy control and the cirrhotic patient 
had normal serum PTHRP levels. 6 out of 13 normocalcemic HCC 
patients had elevated serum PTHRP； among these 6 patients, one 
patient had elevated NcAMP,total urinary cAMP /lOO ml glomerular 
filtrate and total urinary cAMP:creatinine ratio, one patient had 
suppressed serum PTH level and elevated total urinary cAMP : 
creatinine ratio; one patinet had low TMP/GFR and one patient had 
elevated urinary calcium:creatinine ratio. There was also one 
patient in the normocalcemic HCC group who had borderline high 
serum PTHRP level with low PTH concentration. 
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Table U . PTHRP results together with other biochemical findings 
on some patients and healthy control subjects 
reference range in bracket under test 
Subjects Serum Serum Serum Serum TMP/GFR NcAMP UcAflP/ UcAf1P:cr Uca:cr UOHP:cr 
PTHRP calcium phosphate PTH 100ml GF ratio ratio ratio 
(<50*) (2.13-2.51)(0.82-1.4) (10-50) (0.57-1.45**1(0.2-4.64**) (0.94-4.9**) { (716**) ( (0.6”*) ( (30'*^) 
pg/nil Kimol/1 mmol/l pg/ml 關ol/l nmol/lOOmlGF nmol/lOOmlGF nrooi/ininol cr mmol/mmol cr umol/mmol cr 
HYPERCALCEMIC 
HCC 
No.l )400t 3.50个 0,764^ 1.0、!^  0 . 5 4 i 7.56 小 8.06 小 1389个 1.31 个 45 个 
No.2 >400个 2.95个 0.84 2.2 ^  0.61 12.0 个 12.40个 2066个 2.07个 拠个 
NORMOCALCEMIC 
HCC 
No.l 57 2.35 1.22 1.0 4' 1.01 2.56 3.38 476 0.43 9 
No.2 233 f 2.15 1.38 21.0 l . U 6.12 小 7.17 小 732 个 0.07 24 
No.3 UOO个 2.16 0.96 1.0 小 0.92 4.13 4.76 806/f\ 0.13 13 
N0.4 50 2.25 1.06 10.0 1.28 1.12 1.92 198 0.04 14 
No. 5 》400l^ 2.16 1.05 14.0 0.86 3.81 4.15 519 0.74 个 13 
No. 6 32 2.11 1.17 U . O 1.05 3.41 3.97 568 0.20 19 
No. 7 (10 2.04 1.39 21.0 0.85 3.49 5.04 个 458 0.15 12 
No. 8 9 1 1 2.37 1.13 19.0 1.03 3.64 3.94 493 0.37 20 
No.9 23 1.92 1.19 24.0 1.12 1.90 2.71 339 0.06 12 
No. 10 49 2.25 0.97 15.0 0.76 2.28 2.91 265 0.56 10 
No. 11 >4004" 2.15 1.00 22.0 0.98 2.85 3.50 433 0.50 7 
No. 12 1.95 1.13 27.0 0.40 2.25 2.77 223 0.36 10 
No. 13 29 2.54 1.23 24.0 1.22 4.05 4.80 492 0.05 12 
CIRRHOSIS 
No.l 30 2.28 0.95 12.0 0.63 1.57 1.93 264 0.28 50 个 
HEALTHY 
CONTROL 
No.l 47 2.43 1.17 20.0 1.08 1.88 2.77 252 0.40 11 
PTHRP: parathyroid hormone-related peptide; 
PTH: parathyroid hormone； 
TMP/GFR:renal phosphate threshold; 
NcAMP :nephrogenous cyclic adenosine monophosphate; 
UcAflP: total urinary cyclic adenosine monophosphate; 
GF : glomerular filtrate; 
Uca : urinary calcium; 
UOHP: urinary hydroxyproline; 
cr: creatinine; 
HCC: hepatocellular carcinoma; 
个:increase; \ : decrease; 
* reference range provided by Department of Medicine, University of HK; 
** reference range from the healthy control group of this study; 





T h e c A M P k i t u s e d in t h e p r e s e n t s t u d y r e q u i r e s an 
extraction step for plasma samples and pre-dilution step for the 
urine samples. These procedures introduce inherent systematic 
errors affecting the precision of the assay. The assay had good 
^fithin-irim precision with coefficient of variation varied from 
1.3 to 3.5 per cent.The between-run precision was poorer with 
c o e f f i c i e n t of v a r i a t i o n v a r i e d f r o m 1 6 . 3 to 1 7 . 4 p e r 
cent.Imprecision of the assay also increased with concentration 
as judged by the increasing coefficient of variation in the mean 
per cent bound of the standards. 
The overall accuracy of the assay was acceptable. Results of 
both Gilford I and II (means, medians and bias) showed good 
agreement with the assigned values. The positive bias observed in 
the Corning Urine II may be explained. The assigned values in 
that control may not be fully established by the manufacturer 
since it was newly marketed at the time of the assay.The average 
recovery of 90 per cent agreed closely with the recovery provided 
by the kit manufacturer (89 per cent ). 
The incidence of hypercalcemia in HCC patients in this study 
is 7 per cent. This agrees with the incidence of 5.3 per cent in 
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another study [87]• The measurement of serum total calcium may 
not be sensitive enough to detect early actions of PTHRP on HHM 
patients because the renal c a p a c i t y to m a i n t a i n c a l c i u m 
homeostasis is large. PTHRP must have been acting for some time 
before clinical hypercalcemia develops. Another limitation of 
measuring serum total calcium is that in HCC patients, serum 
albumin concentration is significantly decreased. Therefore, 
these patients may appear to have normal serum total calcium 
concentration, but their serum albumin adjusted calcium will be 
increased. In fact,this study has shown that HCC patients had 
higher mean albumin adjusted calcium concentration than the mean 
serum total calcium concentration. 
In severe liver disease, there is a considerable loss of 
functional liver cells resulting in reduced albumin synthesis 
[98]. In this study, HCC and cirrhotic patients had reduced serum 
albumin concentration that reflects the loss of functional mass 
in the liver. 
ALP has been widely used as b i o c h e m i c a l m a r k e r of b o n e 
turnover, although its diagnostic v a l u e s h a v e s i g n i f i c a n t 
limitations because of the p o s s i b l e o s s e o u s and n o n - o s s e o u s 
sources [33]. Serum ALP derives from osteoblasts of bone, the 
hepatobiliary tract, the intestinal wall, the renal tubules and 
the placenta [98]• The increased serum ALP level associated with 
liver disease results from decreased secretion of ALP into the 
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bile and regurgitation of ALP into circulation. In addition, 
cholestasis causes increased synthesis of ALP in the ductule 
c e l l s . C o n s e q u e n t l y , the i n c r e a s e d s e r u m ALP l e v e l in HCC 
patients had little diagnostic value in the evaluation of bone 
resorption. However, if the heat labile fraction of ALP had been 
determined, it may have shed some light on . the origin of raised 
ALP. 
PTHRP has phosphaturic effect of PTH [49,59,60,67]. As in 
PHP, hypercalcemic HCC patients had obvious hypophosphatemia as 
shown by the suppressed serum p h o s p h a t e c o n c e n t r a t i o n and 
TMP/GFR. The impairment of phosphate metabolism in HHM was found 
to be due to the impairment of sodium-dependent phosphate uptake 
at the renal cortical brush b o r d e r m e m b r a n e [49] . In f a c t , 
PTHRP (1-34) was shown to be m o r e p o t e n t than h P T H (1-34) in 
increasing phosphate and cAMP excretion [67] • Although cirrhotic 
patients also had lower serum phosphate concentration than the 
healthy contros, the difference is less marked than hypercalcemic 
HCC patients with healthy controls. Also,the TMP/GFR in cirrhotic 
p a t i e n t s w a s n o t s u p p r e s s e d . Of t h e t w o p a t i e n t s in t h e 
normocalcemic HCC group who had suppressed TMP/GFR, one can be 
explained by having incresed serum PTHRP. 
Hypercalcemic HCC patients, like HHM patients had uniformly 
suppressed serum PTH .Therefore, d e s p i t e the b i o c h e m i c a l 
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s i m i l a r i t i e s w i t h P H P , P T H is d e f i n i t e l y n o t p l a y i n g a 
contributory role in the hypercalcemia of HCC. In the past, the 
measurement of serum PTH had r e l i e d on the b i o - i n a c t i v e C-
terminal fragments of PTH which is cleared by the kidney; this 
causes diagnostic limitation in patients with renal insufficiency 
[99] • With the use of N-terminal and intact PTH assay (used in 
this study), this can be circumvented.The distribution of serum 
PTH in the normocalcemic HCC patients showed that a considerable 
number of them had suppressed serum PTH concentration. This may 
possibly be due to the suppression of PTH secretion by PTHRP even 
before clinical hypercalcemia develops. 
The plasma cAMP levels obtained in this study was lower 
t h a n t h o s e of R u d e 辽 [61] in t h e h e a l t h y 
controls,normocalcemic and hypercalcemic cancer patients (Table 
11)• This study showed that plasma and urine cAMP alone are poor 
indicators of PTHRP bioactivity as they showed no discrimination 
between hypercalcemic HCC p a t i e n t s from n o r m o c a l c e m i c HCC 
patients,cirrhotic patients and healthy controls.Feinglos 红 红 
also showed that there was no significant difference in plasma 
cAMP between PHP patients and healthy control subjects [100]. 
NcAMP is considered to be a sensitive and specific index of 
PTH bioactivity [61-66] and is e l e v a t e d in both PHP and H H M 
patients, suggesting that a humoral factor in HHM stimulates 
NcAMP production via PTH dependent adenyl cyclase .NcAMP alone 
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cannot differentiate between PHP and HHM patients [66]. But in 
the absence of increased serum PTH concentration, NcAMP is a key 
biochemical marker by which HHM p a t i e n t s can be i d e n t i f i e d . 
Patients with m a l i g n a n c y - a s s o c i a t e d h y p e r c a l c e m i a can be 
segregated on the basis of NcAMP excretion [32] . Patients with 
elevated NcAMP had p r e d o m i n a t e l y s q u a m o u s c e l l c a r c i n o m a . 
Conversely, those with low NcAMP excretion were patients from 
breast or haematologic malignancies. 
Healthy control subjects in this study had NcAMP and total 
urinary cAMP/100 ml glomerular filtrate that agrees closely T^ith 
other authors (table 11). H y p e r c a l c e m i c HCC p a t i e n t s h a d 
s i g n i f i c a n t l y e l e v a t e d N c A M P , t o t a l u r i n a r y c A M P / 1 0 0 m l 
glomerular filtrate and total urinary cAMP:creatinine ratio which 
agrees with the findings by other authors (table 11) • Results in 
this study showed that total u r i n a r y c A M P / 1 0 0 ml g l o m e r u l a r 
filtrate and total urinary cAMPrcreatinine ratio which do not 
require the measurement of plasma c A M P , are h a v i n g the s a m e 
discriminatory capacity in differentiating hypercalcemic HCC 
patients from the other patient g r o u p s and from the h e a l t h y 
controls. Stuart also showed that total urinary cAMP:creatinine 
ratio to be slightly superior than NcAMP in discriminating PHP 
from healthy controls [66]. Also, it is technically simpler than 
N C A M P measurement because the assay of plasma cAMP requires an 
extraction step that may introduce additional imprecision. As it 
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has been shown that the increase in cAMP excretion induced by 
PTH infusion is of renal origin [92], then the measurement of a 
constant plasma fraction is obviously unnecessary.This study 
proved the usefullness of total urinary cAMP/100 ml glomerular 
filtrate and total urinary c A M P : c r e a t i n i n e ratio as they 
correlated well with NcAMP (r=0.991 and 0.914; figure 9,11). 
In the normocalcemic HCC group, there was one patient who 
had increased serum PTHRP together w i t h n o r m a l N c A M P but 
i n c r e a s e d t o t a l u r i n a r y c A H P : c r e a t i n i n e r a t i o . T h i s m a y 
illustrate that total urinary c A M P : c r e a t i n i n e r a t i o may be 
slightly better than NcAMP. In the healthy controls, females had 
higher total urinary cAMP/100 ml glomerular filtrate and total 
) urinary cAMP:creatinine ratio than m a l e s ; this c o u l d not be 
explained as there was no significant difference in serum PTH 
between them. In cirrhotic p a t i e n t s , N c A M P , t o t a l u r i n a r y 
cAMP/100 ml glomerular filtrate and total urinary cAMPrcreatinine 
ratios are not elevated , showing that PTHRP is not playing an 
active role in cirrhosis. 
Urinary calcium:creatinine and hydroxyproline:creatinine 
ratios are regarded as reasonably accurate means to assess bone 
resorption [22]. Hypercalcemic HCC patients had increased urinary 
excretion of hydroxyproline thereby suggesting that they had 
increased bone resorption. But as hydroxyproline arises from 
both osseous and non-osseous sources [33], it is not a specific 
marker of bone resorption. In a recent study , osteocalcin (bone-
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Gla-protein ,BGP), a vitamin-K-dependent protein synthesised by 
osteoblasts is suggested to to a specific marker of osteoblasts 
activity [33].They showed that simutaneous measurements of serum 
BGP and urinary hydroxyproline:creatinine ratio improved the 
d i f f e r e n t i a l d i a g n o s i s of h y p e r c a l c e m i a . H i g h u r i n a r y 
hydroxyproline:creatinine r a t i o w i t h h i g h serum BGP l e v e l 
suggests that bone turnover is c o u p l e d ; e l e v a t e d u r i n a r y 
hydroxyproline:creatinine ratio with normal or low serum BGP 
suggests that bone turnover is uncoupled.In HHM patients ,bone 
resorption is uncoupled [41]. The decreased serum BGP in HHM may 
support the role of BGP as a c o u p l i n g f a c t o r b e t w e e n b o n e 
resorption and formation [33]. It has been shown that urinary 
calcium:creatinine and urinary hydroxyproline:creatinine ratios 
are not correlated with the extent of metastatic disease but with 
TMP/GFR [22]. These support the concept that a humoral factor 
with effects on both bone and r e n a l t u b u l e s is c a u s i n g b o n e 
resorption, hypercalcemia and hyperphosphaturia in HHM. 
Ralston et al [22] showed that normocalcemic cancer patients 
had urinary calcium:creatinine r a t i o of b e l o w 0.6 m m o l / m m o l 
creatinine and urinary hydroxyproline:creatinine ratio of below 
30 umol/mmol creatinine.The p r e s e n t s t u d y has shown that 
h y p e r c a l c e m i c H C C p a t i e n t s h a d m e a n v a l u e s of t h e s e t w o 
parameters well above these v a l u e s . W h i l e all other s u b j e c t 




By employing the method d e s c r i b e d by N o r d i n [95], the 
contributions of hypercalcemia in the 4 h y p e r c a l c e m i c HCC 
patients were calculated. The r e s u l t s s h o w e d that the m a j o r 
contributing factor to extracellular calcium is enhanced bone 
resorption. But another study in Hong Kong showed that the major 
hypercalcemic factor in HCC is i n c r e a s e d t u b u l a r c a l c i u m 
reabsorption [7]. Obviously, due to the small number of subjects 
in the hypercalcemic HCC group, it may be premature to conclude 
that bone resorption is the m a j o r c o n t r i b u t i n g f a c t o r to 
hypercalcemia . There are authors who favour the importance of 
tubular reabsorption [22,32,48,49] as the major contributing 
> factor. Furthermore, in many benign disorders such as Gushing's 
s y n d r o m e , i m m o b i l i z a t i o n a n d t h y r o t o x i c o s i s , w h e r e b o n e 
resorption is increased, hypercalcemia does not occur when the 
kidney can usually preserve homeostasis [48]. 
A p p a r e n t l y , both bone r e s o r p t i o n and i n c r e a s e d t u b u l a r 
r e a b s o r p t i o n m u s t a c t s y n e r g i c a l l y to r e s u l t in 
hypercalcemia because in h e a l t h y i n d i v i d u a l s , e l e v a t i o n of 
filtered load of calcium by infusion experiments was accompanied 
by a linear rise of calcium excretion [101]• 
As 6 out of 13 normocalcemic HCC patients had elevated serum 
PTHRP concentrations, the s e n s i t i v i t y of the N c A M P a s s a y in 
detecting early changes in HHM is questioned. Apparently, PTHRP 
• • - — 
is a more sensitive test in detecting patients potentially at 
risk of developing hypercalcemia than NcAMP. The high incidence 
of elevated serum PTHRP and other parameters in normocalcemic HCC 
patients showed that PTHRP must already been acting for some time 
b e f o r e h o m e o s t a s i s c o l l a p s e s a n d h y p e r c a l c e m i a b e c o m e s 
apparent.The reason for the much lower incidence of hypercalcemia 
in HCC may be due to the fact that most of the HCC patients died 
before they have time to develop hypercalcemia. The central role 
of PTHRP can be confirmed as it has been shown that serum PTHRP 
was elevated in 71 per cent of HHM patients, and that serum PTHRP 
correlated positively with serum calcium and negatively with 
‘ serum phosphate concentrations [72]• 
In the single cirrhotic patient and the healthy control, 
serum PTHRP was not elevated and t h e y did not h a v e any 
associated biochemical features of HHM. Thus PTHRP seems to play 
no part in these subjects. 
In conclusion, the results of this s t u d y t e n t a t i v e l y 
indicate that the biochemical features of hypercalcemia in HCC 
patients resemble the classical HHM syndrome. Hypophosphatemia, 
r e d u c e d r e n a l p h o s p h a t e t h r e s h o l d , s u p p r e s s e d s e r u m P T H 
concentration and increased NcAMP excretion were all observed in 
hypercalcemic HCC patients and in some normocalcemic HCC patients 
reflecting the gradual changes in c a l c i u m h o m e o s t a s i s from 
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normocalcemia to hypercalcemia. In cirrhotic patients and healthy 
control subjects, the b i o c h e m i c a l f e a t u r e s of HHM w e r e not 
observed. Bone resorption was increased in hypercalcemic HCC 
patients and appeared to be the m a i n c o n t r i b u t i n g factor to 
hypercalcemia. Although HHM syndrome closely resembles PHP, the 
suppressed serum PTH levels in HHM patients rules out the role of 
PTH in H H M . In parallel with the c h a r a c t e r i s t i c b i o c h e m i c a l 
features in hypercalcemia HCC patients, the concomitant increase 
in serum PTHRP level clearly indicates the central role of PTHRP 
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